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PURPOSE AND PLAN OF THE STUDY 
 Recent technological innovation of combinatorial chemistry and 
high-throughput screening can effectively discover the seeds of new 
drugs, which presents good pharmacological activities. However, since 
many seeds of new drugs discovered by those techniques are poorly 
water soluble, it is often difficult to adopt them as a candidate of new drug 
 Together with the permeability, the solubility behaviour of a drug is a key 
determinant of its oral bioavailability. It is estimated that more than 35% of 
the known drugs and more than 25% of the new discovered appear such 
problems. 
  In the present study Etodolac is the drug been selected, which is a 
member of the pyranocarboxylic acid group of non-steroidal anti-
inflammatory drugs (NSAIDs). It is a white crystalline compound, insoluble 
in water but soluble in alcohols, chloroform, dimethyl sulfoxide and 
aqueous polyethylene glycol.  
  Problems related to poor water solubility, slow dissolution and 
concomitantly low bioavailability can be overcome by using solid 
dispersions, a concept firstly introduced by Sekiguchi and Obi. Solid 
dispersions consist of a hydrophilic carrier in which a hydrophobic drug is 
incorporated. The carrier can be either crystalline or amorphous and the 
drug can be dispersed either molecularly, in amorphous particle or in 
crystalline particles. 1-3 
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 The main perspective of the present study aims at overcoming 
these problems by solid dispersion technology by using traditional carrier 
such as pregelatinized starch from their respective native starch of Potato, 
Tapioca and Maize. Pregelatinized starch is a modified starch that has 
been modified chemically or mechanically to rupture all or part of starch 
granules.4  The objective of the present study is to prepare pregelatinized 
starch from three sources such as Potato, Tapioca and Maize by a known 
method. It is a low cost carrier. Tapioca is cultivated in many regions of 
Tamil Nadu. It is very cheap so that we can reduce the cost of production 
significantly. 
 The research work envisaged was: 
1. Literature survey on Solid dispersion methods and carriers used for 
 solid dispersion 
2. Preparation, Characterization and evaluation of solid dispersions of 
 Etodolac with PGS prepared from Potato, Tapioca and Maize. 
3. Formulation and evaluation of Etodolac compressed tablets from 
 selected Etodolac solid dispersion 
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INTRODUCTION 
 When the drug is administered in a solid dosage form such as tablet 
and capsule it must be released from the dosage form and dissolved in the 
gastrointestinal fluids before it can be absorbed. The bioavailability of 
poorly water soluble drugs is limited by their dissolution rates, which are in 
turn controlled by the surface area that they are present for dissolution. If 
the rate of dissolution of the drug is significantly slower than the rate of 
absorption, the dissolution of the drug becomes the rate limiting step in the 
absorption process, and the particle size of the drug is of great importance 
in the transport from the gastrointestinal tract to the site of action5.  
 Consideration of the modified Noyes-Whitney equation6,7 provides some 
hints as to how the dissolution rate of even very poorly soluble compounds 
might be improved to minimize the limitations to oral availability: 
 
 
 where dC/dt is the rate of dissolution, “A” is the surface are 
available for dissolution, “D” is the diffusion coefficient of the compound, 
“Cs” is the solubility of the compound in the dissolution medium, “C” is the 
concentration of drug in the medium at time t and h is the thickness of the 
diffusion boundary layer adjacent to the surface of the dissolving 
compound. The main possibilities for improving dissolution according to 
this analysis are to increase the surface area available for dissolution by 
dC 
dt 
AD(Cs - C) 
h
=
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decreasing the particle size of the solid compound and/or by optimizing the 
wetting characteristics of the compound surface, to decrease the boundary 
layer thickness, to ensure sink conditions for dissolution and, last but 
definitely not least, to improve the apparent solubility of the drug under 
physiologically relevant conditions. 
 Of these possibilities, changes in the hydrodynamics are difficult to 
invoke in vivo and the maintenance of sink conditions will depend on how 
permeable the gastrointestinal mucosa is to the compound as well as on 
the composition and volume of the lumenal fluids. Although some research 
effort has been directed towards permeability enhancement using 
appropriate excipients, results to date have not been particularly 
encouraging. Administration of the drug in the fed state may be an option 
to improve the dissolution rate and also to increase the time available for 
dissolution; the likely magnitude of the food effect can be forecasted from 
dissolution tests in biorelevant media8. However, the most attractive option 
for increasing the release rate is improvement of the solubility through 
formulation approaches. 
DEFINITION 
  Solid dispersion is defined as the dispersion of one or more active 
ingredients in an inert carrier or matrix at solid state prepared by the 
melting (fusion), solvent or the melting-solvent method. 
 The dispersion of a drug or drugs in a solid diluent or diluents by 
traditional mechanical mixing is not included in this category. The term 
Introduction 
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coprecipitate (more accurately coevaporate) has also been frequently 
used when a solid dispersion is prepared by a solvent method. 
ADVANTAGES OF SOLID DISPERSIONS: 
 Solid dispersion of drugs in solid state is helpful in stabilizing 
 unstable drugs. 
 The PEGs may protect certain drug e.g. cardiac glycosides against 
 the decomposition by saliva and allow buccal absorption. 
  Solid dispersions may be thermodynamically more active form of 
 drug and directly influence the diffusion and release rate. 
  An increased diffusion of steroid from the ointment was obtained. 
 e.g. solid dispersion of prednisolone urea dispersion. 
  Solid dispersion technology can be used to solidify liquid drugs.e.g. 
 clofibrate and benzyl benzoate. 
DISADVANTAGES OF SOLID DISPERSIONS: 
 Tackiness and decommission during preparation and formulation. 
 The oral administration of solid dispersions without concomitant 
 reduction in dose may result in higher incidence of adverse effect. 
 E.g. ulceration of indomethacin-PEG 6000 dispersion. 
 Difficulty in pulverization of solid dispersion. 
 Drug carrier incompatibility. 
 Poor flow and mixing properties. 
 Sifting of the solid dispersions, which are usually soft and tacky. 
Introduction 
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CLASSIFICATION OF SOLID DISPERSIONS 
1.  Simple eutectic mixtures 
 Solid eutectic mixtures are usually prepared by rapid cooling of a 
comelt of two components in order to obtain a physical mixture of very fine 
crystals of the two components. When the preparation is dissolved in 
aqueous medium the carrier will dissolve rapidly, releasing very fine 
crystals of drug which offers large surface area thereby improvement in 
dissolution is effected.9,10  
2.  Solid solutions 
 Solid solutions of a poorly water soluble drug dissolved in a carrier 
with relatively good aqueous solubility are of particular interest as a means 
of improving oral bioavailability. In the case of solid solutions, the drug's 
particle size has been reduced to its absolute minimum viz. the molecular 
dimensions 11 and the dissolution rate are determined by the dissolution 
rate of the carrier. By judicious selection of a carrier, the dissolution rate of 
the drug can be increased by up to several orders of magnitude. Solid 
solutions can be classified according to two methods. First, they can be 
classified according to their miscibility (continuous versus discontinuous 
solid solutions) or second, according to the way in which the solvate 
molecules are distributed in the solvendum (substitutional, interstitial or 
amorphous). 
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A)  Continuous and discontinuous solid solutions: 
1. Continuous solid solutions 
 In a continuous solid solution, the components are miscible in all 
proportions. Theoretically, this means that the bonding strength between 
the two components is stronger than the bonding strength between the 
molecules of each of the individual components. Solid solutions of this 
type have not been reported in the pharmaceutical literature to date.  
2.  Discontinuous solid solutions 
  In the case of discontinuous solid solutions, the solubility of each of 
the components in the other component is limited. 
B)  Substitutional crystalline, interstitial crystalline and 
 amorphous solid solutions: 
1.  Substitutional crystalline solid solutions 
 Classical solid solutions have a crystalline structure, in which the 
solute molecules can either substitute for solvent molecules in the crystal 
lattice or fit into the interstices between the solvent molecules. Substitution 
is only possible when the size of the solute molecules differs by less than 
15% or so from that of the solvent molecules12. 
2. Interstitial crystalline solid solutions 
 In interstitial solid solutions, the dissolved molecules occupy the 
interstitial spaces between the solvent molecules in the crystal lattice. As 
in the case of substitutional crystalline solid solutions, the relative 
molecular size is a crucial criterion for classifying the solid solution type. In 
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the case of interstitial crystalline solid solutions, the solute molecules 
should have a molecular diameter that is no greater than 0.59 of the 
solvent molecule's molecular diameter13. Furthermore, the volume of the 
solute molecules should be less than 20% of the solvent.  
3.  Amorphous solid solutions 
  In an amorphous solid solution, the solute molecules are dispersed 
molecularly but irregularly within the amorphous solvent. Using griseofulvin 
in citric acid, Chiou and Riegelman14 were the first to report the formation 
of an amorphous solid solution to improve a drug's dissolution properties. 
Other carriers that were used in early studies included urea and sugars 
such as sucrose, dextrose and galactose. More recently, organic polymers 
such as polyvinylpyrrolidone (PVP), polyethylene glycol (PEG) and various 
cellulose derivatives have been utilized for this purpose. 
SOLID DISPERSION TECHNIQUES 
1.  Melting or fusion method 
 The melting or fusion method was first proposed by Sekiguchi and 
Obi15 to prepare fast release solid dispersion dosage forms. In this method 
the physical mixture of drug and the water soluble carrier is heated directly 
until it is melted. The melted mixture is then cooled and solidified in an ice 
bath under vigorous stirring. The final mass was crushed, pulverized and 
sieved. The dispersion can also be cooled through the process of spray 
congealing using spray drying equipment. The melted material is sprayed 
onto cold metal surfaces, which forms pellet of the dispersion. This does 
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not require grinding and therefore no alteration of the crystal modification 
of the drug occurs. E.g. solid dispersion of sulphamethoxazole, 
acetaminophen, chloramphenicol, tolazamide, steroids. 
Advantages 
 Simplicity and economy. 
 This method also advantageous for compounds, which do not 
 undergo significant thermal degradation 
 Super saturation of a solute or drug in a system can often be 
 obtained by quenching of the melt rapidly from high temperature. 
Disadvantages 
 The main disadvantage of the melt method includes thermal 
degradation, sublimation and polymeric transformation, which can 
affect the physicochemical properties of the drug including its rate 
of dissolution. 
 The temperature at which the dispersion solidifies affects 
crystallization rate and may alter both the size of the crystal and 
hardness of the dispersion. This may result in tacky or glassy and 
unmanageable dispersions, which will require storage at elevated 
temperature to facilitate hardening.  
2.  Solvent evaporation method 
 This method involves dissolving the drug and carrier in a suitable 
organic solvent followed by evaporation of the solvent to form solid 
dispersion involves dissolving the drug and carrier in a suitable organic 
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solvent followed by evaporation of the solvent to form solid dispersion. The 
mass was then stored in dessicator, pulverized and sieved. removal is 
accomplished by various means. The most common approach is the 
application of reduced pressure at a fixed temperature to evaporate the 
organic solvent. Temperatures of 1250C for 25 minutes, 1150C for one 
hour16, -50c and reduced pressure followed by drying for 12 hours in 
vacuum have been used17. Spray drying is another approach by which 
solvent removal can be accomplished and it is probably the fastest way of 
removing solvent18,19. The freeze drying technique is also employed to 
prepare solid dispersions by removal of aqueous solutions20,21. E.g. solid 
dispersion of β-carotene-PVP, griseofulvin-PVP and reserpine-deoxy 
cholic acid. 
Advantages 
 The procedure is suitable for drugs that are thermo labile. 
 The thermal decomposition of drugs or carriers can be prevented 
because of the low temperature required for the evaporation of the 
organic solvents.  
 For aqueous system, frozen temperature can be used to evaporate 
the solvent, which can enhance the integrity of the drug. 
 Disadvantages 
 Difficulty in complete removal of solvent. 
 Finding a suitable solvent that will dissolve both the drug and carrier 
is very difficult. 
Introduction 
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 Plasticization of some polymers such as poly vinyl pyrrolidone has 
occurred with the use of some solvents. 
 It is important that the rate of evaporation of a solvent is controlled 
so as to control the particle size of the drug. This in turn will affect 
the rate of dissolution of the drug in the solid dispersion. 
3.  Fusion-solvent method 
 In the fusion solvent method, a carrier(s) is/are melted and the 
drug(s) is/are incorporated in the form of a solution. If the carrier is capable 
of holding a certain proportion of liquid yet maintaining its solid properties, 
and if the liquid is innocuous, the need for removal is eliminated. This 
method is particularly useful for drugs that have high melting points are 
that are thermo labile. The feasibility of the method has been 
demonstrated for spironolactone and griseofulvin dispersions in 
polyethylene glycol 6000(PEG 6000) 22. E.g. solid dispersion of clofibrate, 
methyl salicylate, benzyl benzoate. 
 MECHANISM OF INCREASED DISSOLUTION RATE BY SOLID 
DISPERSION SYSTEM 
 In the case of glass solutions, and amorphous dispersions, particle 
size is reduced to a minimum level. This can result in an enhanced 
dissolution rate due to both an increase in surface area and 
solubilization. 
 The carrier material as it dissolves may have a solubilization effect 
on the drug. 
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  The carrier material may also have an enhancing effect on the 
wettability and dispersibility of the drug in the dissolution medium. 
Then should retard any agglomeration or aggregation of the 
particles, which can slow the dissolution process. 
 Formation of metastable dispersion that has a greater solubility 
would result in faster dissolution rates.23 
APPROACHES TO IMPROVE THE SOLUBILITY OR TO INCREASE 
THE AVAILABLE SURFACE AREA FOR DISSOLUTION 
I.  Physical modifications 
• Particle size 23 
o Micronization 
o Nanosuspensions 
• Modifications of the crystal habit 
• Polymorphs 
• Pseudo polymorphs (including solvates) 
• Complexation/solubilization 
o Use of surfactants 
o Use of cyclodextrines 
• Drug dispersion in carriers 
o Eutectic mixtures 
o Solid dispersions (non-molecular) 
o Solid solutions 
Introduction 
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II.  Chemical modification 
• Soluble prodrugs 
• Salts 
CARRIERS USED FOR SOLID DISPERSION SYSTEMS 
1. Polyethylene glycols (PEGs) 23 
2. Polyvinylpyrrolidone (PVP) 
3. Polyvinyl groups  
o Polyvinyl alcohol (PVA) 
o Crospovidone  
o Polyvinylpyrollidone-polyvinylacetate copolymer (PVP-PVA) 
4. Cellulose derivatives  
o Hydroxypropylmethylcellulose (HPMC) 
o Hydroxypropylcellulose (HPC)  
o Carboxymethylethylcellulose (CMEC) 
o Hydroxypropylmethylcellulose phthalate (HPMCP) 
5. Polyacrylates and polymethacrylates 
o Eudragit E  
o Eudragit L 
6. Urea 
7. Sugar, polyols and their polymers 
o Dextrose  
o Sucrose  
8. Emulsifiers  
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o Sodium Lauryl Sulphate  
o Tween 80 
9. Organic acids and their derivatives 
o Succinic acid  
o Citric acid 
10. Other carriers  
o Phospholipid  
o Pentaerythritol 
11. Modified starches 
a) Pregelatinized (pregelled) starch 
b) Chemically modified starches 
o Hydroxy ethyl starch 
o Hydroxy propyl starch 
o Sodium starch glycolate  
MODIFIED STARCHES  
 There have been numerous attempts to modify starch to improve 
different properties, mostly for use in commercial food products. The types 
of modifications used can be classified as either physical(no new chemical 
bonds formed) or chemical (new chemical bonds formed).Some types of 
modified starches may require both chemical and physical modification.24 
Pregelatinized (Pregelled ) Starch  
 When starch is heated eventually the pressure inside the starch 
grain will increase to such an extent that the grain ruptures. When the 
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starch grain is ruptured the inner amylose component of the starch is no 
longer totally encapsulated by the outer amylopectin layer, and this has 
significant implications for the physical properties of the starch. 
  The rupture of the starch grain is referred to a gelatinization, and 
the temperature at which it occurs is known as gelatinization temperature. 
This temperature varies according to the botanical source of the starch. It 
is not a sharp change with temperature but typically occurs over a rang of  
10 0C-150C. 
  If starch grains are heated in air to a suitable temperature , the 
grains will still rupture but, in the absence of a suitable medium to dissolve 
the amylose, the amylose will remain mostly inside the amylopectin sacs. 
Such starches are referred to as pregelatinized or pregelled starches. 
Examined under the microscope the ruptured starch grains will have a 
characteristic slit in the amylopectin coat. Depending on the temperature 
used and the time of exposure of the starch grain to the heat, it is possible 
to obtain starches that are pregelatinized to different extents. The extent of 
pregelatinization has a major influence on their physical properties and 
thus their suitability for use in different applications. 
 One property that is changed and has implications for use in tablet 
formulations is the solubility of the pregelatinized starch. Fully 
pregelatinized starches are cold water soluble and have little or no 
disintegrant activity. Indeed they may retard disintegration and dissolution, 
particularly after aqueous granulation. The compactilibility of fully 
pregelatinized starch is also poor. It is used as a wet granulation binder. 
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 By contrast, partially pregelatinized starches have good compaction 
properties and retain adequate disintegrant activity. They may be used in 
direct compression formulations as both a filler / binder and as a 
disintegrant. The typical grades of partially pregelatinized starch used in 
the pharmaceutical industry are about 20% pregelatinized. 
 Partially pregelatinized starch may be used as a direct compression 
binder/filler and as a disintegrant. Use levels as a direct compression 
disintegrant are typically around 15% by weight. It can be used at higher 
as a direct compression binder/filler.24 
Chemically Modified Starches  
 Three chemically modified starches that are used in pharmaceutical 
formulations are hydroxyl ethyl starch, hydroxyl propyl starch, and sodium 
starch glycolate. The permitted modifications are acid-modified, bleached, 
oxidized, esterified, etherified or modified enzymatically. The stated intent 
of these modifications is to change the functionality of the starch.24. 
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NON – STEROIDAL ANTI-INFLAMMATORY 
DRUGS 
 
 Non- steroidal anti-inflammatory drugs (NSAIDs) are among the 
most widely used for all therapeutic agents. They are frequently prescribed 
for 'rheumatic' musculoskeletal complaints and are often taken without 
prescription for minor aches and pains. 
 NSAIDS include a variety of different agents of different chemical 
classes. Most of these drugs have three major types of effect. 
• Anti-inflammatory effects: Modification of the inflammatory reaction. 
• Analgesic effect: reduction of certain sort of pain 
• Antipyretic effect: lowering of a raised temperature. 
In general, all of these effects are related to the primary action of the 
drugs-inhibition of arachidonate cyclooxygenase (COX) and thus inhibition 
of the production of prostaglandins and thromboxanes, though some 
aspects of the action of individual drugs may occur by different 
mechanisms.25 
ANTIPYRETIC EFFECTS 
 Normal body temperature is regulated by a centre in the 
hypothalamus which ensures a balance between heat loss and heat 
production. Fever occurs when there is a disturbance of this hypothalamic 
'thermostat' that leads to the set point of body temperature being raised. 
NSAIDs reset the thermostat. The mechanisms of the antipyretic action of 
NSAIDs - Brief Review 
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the NSAIDs are thought to be due largely to inhibition of prostaglandin 
production in the hypo-thalamus.  
ANALGESIC EFFECT  
 NSAIDs are mainly effective against pain associated with 
inflammation or tissue damage because they decrease production of the 
prostaglandins that sensitive nocicepters to inflammatory mediators such 
as bradykinin. Therefore they are effective inarthritis, bursitis, pain of 
muscular and vascular origin, toothache, dysmenorrhoea, the pain of 
postpariem states and the pain of cancer metastasis in bone, all conditions 
that are associated with increased prostaglandin synthesis. There is some 
evidence that they have a central effect by an action mainly in the spinal 
cord.Clinical data indicate that certain NSAIDs are effective in the control 
of some types of severe pain unrelated to inflammation. 
ANTI – INFLAMMATORY EFFECT 
 Drugs such as the NSAIDs reduce mainly those components of the 
inflammatory and immune response in which the products of COX-2 action 
play a significant part, namely: 
• Vasodilatation  
• Oedema 
• Pain 
 COX inhibitors, per se, have no effects on those processes that 
contribute to tissue damage in chronic inflammatory conditions such as 
rheumatoid arthritis, vasuclitis and nephritis. Infact, because some 
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prostaglandins decrease lysosomal enzyme release reduces the 
generation to toxic O2 products inhibit lymphocyte activation, NSAIDs 
could actually exacerbate tissue damage in the long term. 
CLASSIFICATION OF NSAIDs 
 The various analgesic –antipyretic anti-inflammatory agents are 
classified as26 
1. Acidic Drugs  
a.  Salicylates:  
   E.g. Salicylic acid, Apirin 
b.  Para-amino phenols:  
  Eg:Paracetamol 
c.  Pyrazolones:  
  Eg: Phenylbutazone, Suxibuzone  
d.  Indole acetic acids: 
  Eg:Indomethacin, clamidoxic acid  
e.  Propionic acids: 
  Eg: Ibuprofen, Diclofenac 
f.  Aryl anthranilic acids: 
  Eg: Meclofenamic acid, Tolfenamic acid 
g.  Miscellaneous agents: 
  Eg: Piroxicam, Fenoxicam 
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2. Basic Drugs 
 Eg: Timegadine, inhibits neutrophil degranulation and superoide 
production  
2.  Non-Acidic Drugs: 
  Eg: Indoxole Nictimodole  
CLASSIFICATION OF NSAIDs BY CHEMICAL STRUCTURE: 
1.  Carboxylic Acid Groups:  
♦ Salicylates (Acetylsalicylate, Choline Salicylate, Diflunisal, 
Magnesium choline Salicylate, Magnesium Salicylate, Salsa late) 
♦ Acetic Acids (Diclofenac sodium, Diclofenac potassium, Etodolac, 
Indomethacin, Ketorolac, Nabumetone, Sulindac, Tolmetin) 
♦ Propionic acids (Carprofen, Fenoprofen, Flubiprofen, Ibuprofen, 
Ketoprofen, Loxoprofen, Naproxen, Naproxen sodium, Oxaprozin, 
Vedaprofen) 
♦ Anthranilic acids (Meclofenamic acid, Meclofenamate sodium, 
Tolfenamic acid)  
♦ Phenylacetic acids (Acetaminophen) 
♦ Amino nicotinic acids (Flunixin) 
♦ Indole Analogs (Indomethacin, Nabumetone, Ketorolac, Etodolac,) 
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2. Enolic Acid Groups (which doesn't have carboxylic group but 
acid due to the enolic Hydroxy substituent) 
♦ Pyrazolones (Phenylbutazone, Oxyphenbutazone, Dipyrone, 
 Ramifenazone) 
♦ Oxicams (Aceclofenac, Piroxicam, Tenoxicam) 
3.  Coxibs 
 Celecoxib, Rofecoxib, Vladecoxib, Parecoxib, Etoricoxib  
4.  Gold Salts 
 Auranofin, Gold sodium thiomalate, Aurothioglucose  
MECHANISM OF ACTION 
 The main action of NSAIDs is inhibition of arachidonate cyclo 
oxygenase. COX is a bifunctional enzyme, having two distinct activities, 
the main cyclo-oxygenase action which gives PGG2, and a peroxidase 
action which converts PGG2 to PGH2. Different NSAIDs inhibit the 
enzyme by different mechanisms. 
BIOSYNTHESIS OF PROSTAGLANDINS 
 The biochemical effect of NSAIDs includes inhibition of lysosomal 
membrane stabilization, inhibition of the biosynthesis of 
mucopolysaccharides, uncoupling oxidative phosphorylation, fibrinolytic 
activity, sulfahydryl disulfide stabilization. Collagenase production and at 
times suppression of lymphocytic functions.  
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Cyclooxgenase catalyses two enzymatic process 
♦ The incorporation of oxygen in a dioxygenase step to form PGG2.    
♦ The subsequent peroxidation to PGH2. The reaction is initiated by 
the stereospecific abstractin of hydrogen at C13 followed by oxygen 
attach at C11 and C15. 
♦ Most of NSAIDs act by inhibiting cyclooxygenase by preventing the 
abstractin of hydrogen from C13 and therefore peroxidatin at C11 and 
C15. 
 Prostaglandins potentiate the early inflammatory response causing 
vasodilatation, increases permeability, facilitating cellular infiltration land 
sensitizing the pain receptors to bradykinin. The NSAIDs inhibit both the 
synthesis and release of prostaglandins. 
 
ADVERSE EFFECTS 
1. Side effect that occurs at analgesic dose (0.3-1.5g/day) 
 Nausea, vomiting, epigastric distress, increased occult blood loss in 
stools. The most important adverse effect of NSAIds is gastric mucosal 
damage and peptic ulceration.  
2.  Hypersensitivity and idiosyncrasy 
 Though infrequent, there can be serious reactions, which include 
rashes, urticaria, rhinorrhea, angiodema, asthama and anaphylactic 
reaction. Profuse gastric bleeding occurs in rare instance. 
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3. Anti – inflammatory dose (1-2g/day) 
 It will produce the syndrome called salicylism- dizziness, tinnitus, 
vertigo, reversible impairment of hearing and vision, excitement and 
mental confusion, hyperventilation and electrolyte imbalance. 
4. Gastric Mucosal Damage 
 All NSAIDs to varying extent produce gastric pain, mucosal erosion 
or ulceration and blood loss. 
5. Renal effect 
 Conditions leading to hypovolemia, decreased renal perfusion and 
Na+ loss induce renal prostaglandin synthesis which brings about intra 
renal adjustment by promoting vasodilation, inhibiting tubular reabsorption 
and opposing ADH action.26 
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DRUG PROFILE 
Etodolac 
  Etodolac is a member of the pyranocarboxylic acid group of 
nonsteroidal anti-inflammatory drugs (NSAIDS). Etodolac is a racemic 
mixture of [+] S and [-] R enantiomers.27 
Chemical Name  
 ( + ) 1,8- diethyl - 1,3,4,9 - tetrahydropyrano - [ 3,4 -b] indole - 1- 
acetic acid. 
Molecular Formula  
 C 17H 21NO3 
Chemical Structure 
 
 
 
 
Characteristics 
  A white or almost white, crystalline powder,practically insoluble in 
water, freely soluble in alcohols, acetone, chloroform, dimethyl sulfoxide 
and aqueous polyethylene glycol.27 
CH2CH3 
H
N
CH2CH3 
CH2COOH 
O
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Table:1 Typical Properties of Etodolac 
Melting Point 144 0 C-150 0C 
Molecular Weight 287.36 
pKa 4.65 
N-octanol: Water partition coefficien 11.4 at pH 7.4 
Hygroscopicity Non-hygroscopic 
 
CLINICAL PHARMACOLOGY  
Pharmacodynamics 
 Etodolac is a nonsteroidal anti-inflammatory drug that exhibits anti-
inflammatory, analgesic and antipyretic activities in animal models. The 
mechanism of action of Etodolac, is not completely understood, but may 
be related to prostaglandin synthetase inhibition. 
  Etodolac is a racemic mixture of [-] R and [+] S Etodolac. As with 
other NSAIDs, it has been demonstrated in animals that the [+] S form is 
biologically active.Both enantiomers are stable and there is no [-] R to [+] S 
conversion invivo.28 
PHARMACOKINETICS 
Absorption 
 Based on mass balance studies, the systemic availability of 
Etodolac from either the tablet or capsule formulation is atleast 80%. 
Etodolac doesnot undergo significant first-pass metabolism following oral 
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administration. Mean peak plasma concentration (Cmax) range from 
approximately 14 ± 4 to 37 ± 9 mcg/ml after 200 to 600 mg single doses 
and are reached in 80 ± 30 minutes. The extent of absorption of Etodolac 
is not affected when Etodolac is administered after a meal. Food intake, 
however reduces the peak concentration reached by approximately  
one-half and increases the time to peak concentration by 1.4 to 3.8 hours. 
Distribution 
  The mean apparent volume of distribution of Etodolac is 
approximately 390ml/kg. Etodolac is more than 99% bound to plasma 
proteins, primarily to albumin. The free fraction is less than 1% and is 
independent of Etodolac total concentration over the dose range studied. 
Metabolism 
 Etodolac is extensively metabolized in the liver. The metabolites 
include 6,7 and 8-hydroxylated Etodolac and Etodolac glucuronide. 
Excretion 
 The mean oral clearance of Etodolac following oral dosing is  
4 ( ± 16 ) ml/h/kg. Approximately 1% of a Etodolac dose is excreted 
unchanged in the urine with 72% of the dose excreted into urine as parent 
drug plus metabolite 
  Etodolac unchanged 1% 
  Etodolac glucuronide 5% 
  Hydroxylated metabolites( 6,7 and 8-OH ) 13 % 
  Hydroxylated metabolite glucuronides 20% 
  Unidentified metabolities 33% 
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 The terminal half-life( t½ ) of Etodolac is 6.4 hours.Fecal excretion 
accounted for 16% of the dose.28 
Indications and usage 
 Etodolac tablets are indicated: 
For acute and long term use in the management of signs and symptoms of 
the following: 
1. Osteoarthritis. 
2. Rheumatoid arthritis. 
3. Juvenile rheumatoid arthritis. 
 For the management of acute pain 
Contraindications  
¾ Treatment of peri-operative pain in setting of coronary artery bypass 
 graft surgery  
¾ Hypersensitivity to Etodolac 
¾ Patients who have experienced asthma,urticaria,or allergic-type 
reactions after taking Aspirin or other NSAIDs; severe , even fatal 
anaphylactic like reactions have been reported. 
Drug Interactions 
  Etodolac diminish the antihypertensive effect of ACE inhibitors. 
Antacids can decrease the peak concentration of Etodolac reached by 
15% to 20% but have no detactable effect on the time to peak. When 
Etodolac is administered with aspirin, its protein binding is reduced, 
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although clearance of free Etodolac is not altered. Etodolac through effects 
on renal prostaglandins may cause changes in the elimination of 
cyclosporine, Digoxin and Methotrexate leading to elevated serum levels 
and increased toxicity.Nephrotoxicity associated with cyclosporine may 
also be enhanced. Etodolac can reduce the natriuretic effect of 
Furosemide and thiazides in some patients, an elevation of plasma lithium 
levels;phenylbutazone causes increase in the free fraction of Etodolac. 
The effects of Warfarin and Etodolac on GI bleeding are synergistic. 
Adverse drug reactions 
Common 
1. Cardiovascular: edema 
2. Gastro intestinal: Abdominal pain, Diarrhoea, Flatulence, 
 Indigestion, Nausea 
3. Neurologic : Dizziness 
4. Other: Malaise 
Serious 
1. Cardiovascular : CHF,hypertension,MI 
2. Dermatologic : Scaling eczema,stevens-Johnson syndrome 
3. Gastro intestinal : Gastro intestinal haemorrhage,Gastro intestinal 
 perforation,Inflammatory disorder of digestive tract 
4. Haematologic : Agranulocytosis,anaemia,thrombocytopenia 
5. Hepatic : Hepatitis, Jaundice 
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6. Immunologic : Anaphylactoid reaction,immune hyper sensitivity 
 reaction. 
7. Neurologic : Cerebrovascular accident 
8. Renal : papillary necrosis,renal failure. 
9. Respiratory : bronchospasm.28 
DOSE AND ADMINISTRATION 
 Analgesia  
 The recommended total daily dose of Etodolac for acute pain is 
upto 1000mg,given as 200-400 mg every 6 to 8 hours. 
 Osteoarthritis and Rheumatoid arthritis  
 The recommended starting dose of Etodolac for the management of 
the signs and symptoms of osteoarthritis or rheumatoid arthritis is : 300 mg 
b.i.d, t.i.d or 400 mg b.i.d or 500 mg b.i.d. A lower dose of 600 mg/day may 
suffice for long-term administration.28 
 Administration : Oral 
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POLYMER PROFILE 
PRE-GELATINIZED STARCH 
1. Nonproprietary names 
 BP: Pregelatinized starch 
 Ph Eur : Amylum pregelificatum 
  USPNF : Pregelatinized starch29 
2.  Synonyms 
 Compressible starch ; Instastarch ; Lycatab C ; Lycatab PGS; 
Merigel ; National 78-1551 ; Pharma-Gel ; Prejel ; Sepistab ST 200 ; 
Spress B820 ; Starch 1500 G ; Tablitz ; Unipure LD ; Unipure WG22029  
3.  Chemical Name 
 Pregelatinized starch 
4.  Empirical formula Molecular weight 
  ( C6 H 10 O5 ) n Where n = 300-1000 
5. Composition 
 Free amylose   5% 
 Free amylopectin   15% 
  Unmodified starch  80% 
6 Functional category 
 Tablet and capsule diluent, tablet and capsule disintegrant, tablet 
binder. 
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7. Description 
 Pregelatinized starch occurs as a moderately coarse to fine, white 
to off-white colored powder. It is odorless and has a slight characteristic 
taste.29 
8.  Table : 2 Types of starch used 
Starch Botanical source Comments 
Maize(corn) Zea mays The traditional starch used in the formulation of tablets. Widely used 
Potato Solanum tuberosum 
Has also been used for many years 
in tablet manufacture. Less widely 
used than corn starch 
Tapioca Manihot esculenta Appears to be comparable to rice starch in many respects. 
  
9. Typical properties 
 Acidity/alkalitinity :  pH = 4.5-7.0 for a 10% w/v aqueous  
   dispersion. 
 Angle of repose :  40.7 0 
 Density(bulk)  :  0.586g/cm3 
 Density (tapped) :  0.879g/cm3 
  Density (true)  :  1.516g/cm3 
 Flowability  : 18-23% 
 Moisture content :  Pregelatinized starch is hygroscopic. 
 Specic surface area  :  0.26m2/g 
 Viscosity ( dynamic )  :  8-10 mPa s (8-10 cP ) for a 2% w/v  
   aqueous dispersion at 25 0C 29 
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10. Solubility 
 Practically insoluble in organic solvents.Slightly soluble in cold 
water, depending upon the degree of pregelatinization.Pastes can be 
prepared by sifting the pregelatinized starch into, stirred ,cold water.Cold 
water-soluble matter for partially pregelatinized starch is 10-20%. 
11. Preparation of pregelatinized starch 
 An aqueous slurry (100 ml) of starch (40%) w/v containing 1% 
Tween-80 was heated to 650C with continuous stirring until the starch 
gelatinizes and produces a viscous translucent mucilage. The viscous 
mucilage was then dehydrated by the addition of acetone while stirring and 
the solids separated were collected by filtration and further dried at 450C 
for 2 hrs. The dried mass obtained was crushed, pulverized and sifted 
through mesh no.120. 
12. Stability and storage conditions 
 PGS is a stable but hygroscopic material, which should be stored in 
a well-closed container in a cool, dry place. 
13. Safety 
 PGS and starch are widely used in oral solid dosage formulations. 
PGS is generally regarded as a nontoxic and nonirritant excipient. 
However, oral consumption of massive amounts of PGS may be harmful. 
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14. .Applications in pharmaceutical formulation or technology 
1. PGS is a modified starch used in oral capsule and tablet 
formulations as a binder, diluent and disintegrant. 
2. Grades of pregelatinized starch may be produced with enhanced 
flow and compression characteristics such that the pregelatinized 
material may be used as a tablet binder in dry-compression 
process. 
3. PGS may also be used in wet granulation processes.29 
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REVIEW OF LITERATURE 
¾ Vijayakumar SG et al., 38 ( 2005 ) have studied the improvement of 
aqueous solubility and dissolution rate by preparing physical 
mixture and solid dispersion with skimmed milk . Enhancement of 
aqueous solubility of MLX was observed with solid dispersion of the 
drug with skimmed milk due to amino acids and surface active 
agents content in the milk, which can be used for the treatment of 
gastric disturbance. Rotary vacuum evaporation technique was 
used to prepare solid dispersion. Results showed that the solubility 
of solid dispersion of the drug was almost three times greater than 
the pure drug. Similarly, the solid dispersion of the drug indicated a 
significant improvement in the dissolution of the drug as compared 
to the physical mixture and the pure drug. Differential scanning 
calorimetry, X-ray diffraction and scanning electron microscopic 
analysis revealed the formation of solid dispersion of the drug with 
skimmed milk. 
¾ Okonogis et al.,39 ( 2006 ) have studied the dissolution improvement 
of high drug loaded solid dispersion system consisting of drug, 
carrier and surfactant. Solid dispersions of a water-insoluble 
ofloxacin (OFX) with polyethylene glycol (PEG) of different 
molecular weights, namely binary solid dispersion systems, were 
prepared at drug to carrier not less than 5:5. Polysorbate 80, a 
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nonionic surfactant, was incorporated into the binary solid 
dispersion systems as the third component to obtain the ternary 
solid dispersion systems. The powder x-ray diffraction and 
differential scanning calorimetric studies indicated that crystalline 
OFX existed in the solid dispersions with high drug loading. 
However, a decreased crystallinity of the solid dispersions obtained 
revealed that a portion of OFX was in an amorphous state. The 
results indicated a remarkably improved dissolution of drug from the 
ternary solid dispersion systems when compared with the binary 
solid dispersion systems. This was because of polysorbate 80, 
which improved wettability and solubilized the non–molecularly 
dispersed or crystalline fraction of OFX. 
¾ MM Patel and DM Patel 40 ( 2006 ) were prepared solid  
dispersions of Valdecoxib with Mannitol, poly ethylene glycol 4000, 
and PVP K-12 with a view to increase its water solubility. 
Valdecoxib solid dispersion with polyvinyl pyrolidone K-12 showed 
maximum drug release hence, the tablet formulation containing 
valdecoxib polyvinyl pyrolidone K-12 solid dispersion, was prepared 
with a view to improve its water solubility. The dissolution profile of 
best laboratory developed formulation (F1) was compared with 
marketed tablet products. The drug release profile was studied in 
0.1 N HCL. F1 gave far better dissolution than the conventional 
marketed tablet, which released only 44.3% drug and valdecoxib in 
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b cyclodextrin, which released 53.4% drug in 20 min, while F1 
exhibited almost 100% drug release in 20 min. The dissolution 
efficiency of F1 was compared with pure drug, conventional market 
tablet, and valdecoxib in b cyclodextrin. F1 showed maximum 
dissolution efficiency. F1 was considered better than valdecoxib in 
b cyclodextrin, as far as the cost of raw materials used in the 
product is concerned. F1 was subjected to stability studies. The 
formulation was found to be stable for 4 weeks at 45°, with 
insignificant change in the hardness, disintegration time, and in vitro 
drug release pattern. 
¾ Wang et al.,41 ( 2006 ) have studied the oral composition and 
preparative methods of solid dispersion of glibenclamide. The solid 
dispersion containing glibenclamide 2-60% and disperse medium 
98-40% by the ratio of weight. The glibenclamide disperse in the 
disperse medium by the form of unformed, molecule or 
microcrystal. The solid dispersion can be prepared by the methods 
of triturate, fusion or spray drying. According to the preparative 
methods of said, the solid dispersion of glibenclamide is harmless 
and pollution-free. And the operation of methods is conveniently. 
The solid dispersion can improve the solubility materially, improve 
the bioavailability and the stability of thermodynamics of preparation 
of glibenclamide. 
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¾ Barakat NS et al.,42 ( 2006 ) have studied the formation of melt 
dispersion as an effective method of increasing the dissolution rate 
of poorly soluble drugs and of improving the bioavailability. The 
carrier fusion method was used to prepare different dispersion of 
etodolac using Gelucire 44/14 and D-alpha-tocopheryl polyethylene 
glycol 1000 succinate (TPGS). The physical characteristics of the 
binary systems were determined by differential scanning calorimetry 
(DSC), infrared spectroscopy (IR). The release rate from the 
resulting dispersion was determined from dissolution studies by use 
of USP dissolution apparatus II (paddle method). The dissolution 
rate of etodolac is increased in all the dispersion systems compared 
to that of pure drug. A liquid dispersion system of etodolac (20%) 
and Gelucire 44/14: TPGS blend (80%), in different ratios, was also 
prepared. The capsule formulation was subjected to stability studies 
at different temperature and humidity conditions as per ICH 
guidelines. Physical and chemical properties of the dispersion didn't 
change during a period of storage at room temperature and at  
4 degrees C, 0% RH. It was found that etodolac was chemically 
stable against the effects of temperature and humidity. However, 
the relative humidity and storage time exerted an effect on the 
dissolution behavior of etodolac. The changes in dissolution 
behavior after storage under conditions of high humidity and 
temperature might be related to the formation of etodolac 
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microcrystal and to water absorption by the carrier during storage. It 
is predicted that acceptable shelf-lives should result when moisture-
resistant packaging is used for pharmaceutical formulations of this 
type. 
¾ Uchino  T et al.,43 (2007) were prepared solid 
dispersions of Spironolactone with porous silica ( sylysia 730 and 
sylysia 350 ) by the solvent method. The physicochemical 
properties of the prepared solid dispersions were evaluated by 
powder X-ray diffractometry (PXRD), differential scanning 
calorimetry (DSC), scanning electron microscopy (SEM), and 
atomic force microscopy (AFM). The results of PXRD and DSC data 
in the solid dispersion of the Sylysia 350:SPI system (weight ratio of 
1:1) indicated that the molecular state of the adsorbed SPI changed 
from crystalline to amorphous. Although the decrease in the SPI 
concentration increased with the amorphous fraction in the solid 
dispersion, the diffraction peaks due to SPI crystals still remained in 
the solid dispersion of a Sylysia 730:SPI system (weight ratio of 
1:1), indicating that the mean pore diameter and specific surface 
area of an additive are some of the important factors for the 
amorphization of SPI crystals. The dissolution property of the SPI 
from the solid dispersions was remarkably improved in comparison 
with that of SPI crystals. The dissolution rate of the SPI from the 
solid dispersions with Sylysia 350 was faster than that of the SPI 
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from the solid dispersions with Sylysia 730. The difference in the 
dissolution properties of SPI from both the solid dispersions was 
attributed to the difference in the molecular state of the SPI in both 
the solid dispersions. In the stability test, the amorphous state of the 
SPI in the solid dispersion of the Sylysia 350:SPI system (weight 
ratio of 1:1) was maintained for 2 weeks at 25 degrees C and 0% 
RH, while the amorphous SPI without Sylysia 350 crystallized under 
the same conditions. 
¾ Gerrit S. Zijlstra et al ., 44 ( 2007 ) has been developed a respirable, 
inulin- based solid dispersion containing cyclosporine for lung 
transplant patients. The solid dispersions were prepared by spray 
freezedrying. The solid dispersion was characterized by water 
 vapor uptake, specific surface area analysis, and particle size 
analysis. Furthermore, the mode of inclusion of CsA in the 
dispersion was investigated with Fourier transform infrared 
spectroscopy. Finally, the dissolution behavior was determined and 
the aerosol that was formed by the powder was characterized. The 
powder had large specific surface areas (~ 160 m 2 ). The water 
vapor uptake was dependant linearly on the drug load. The type of 
solid dispersion was a combination of a solid solution and solid 
suspension. 
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¾ Minsuk Lee et al.,45 ( 2007 ) have studied the enhancement of 
solubility of Sibutramine free base by preparing the solid dispersion 
using a fluid-bed granulator. The solid dispersion containing 
sibutramine freebase was characterized by differential scanning 
calorimetry (DSC) and powder X-ray diffraction (XRD). After filling 
the sibutramine solid dispersion in the gelatin hard capsule, we 
performed in vitro dissolution test, the stability test under 
accelerated conditions and pharmacokinetic study in beagle dogs. 
The DSC and XRD data showed that sibutramine solid dispersion 
would be amorphous state. The dissolution rate of sibutramine solid 
dispersion was significantly increased about 70% than sibutramine 
freebase. The stability of sibutramine solid dispersion capsules was 
equivalent or above to commercial product of sibutramine. 
¾ Shah T J et al.,46 (2007) have studied the improvement of 
dissolution rate of Rofecoxib, a poorly water soluble drug by solid 
dispersion technique using a water soluble carrier, poloxamer 188 
(PXM). The melting method was used to prepare solid dispersions. 
A 3(2) full factorial design approach was used for optimization 
wherein the temperature to which the melt-drug mixture cooled 
(X(1) ) and the drug-to-polymer ratio (X(2) ) were selected as 
independent variables and the time required for 90% drug 
dissolution (t(90)) was selected as the dependent variable. Multiple 
linear regression analysis revealed that for obtaining higher 
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dissolution of RXB from PXM solid dispersions, a low level of X(1) 
and a high level of X(2) were suitable. The differential scanning 
calorimetry and x-ray diffraction studies demonstrated that 
enhanced dissolution of RXB from solid dispersion might be due to 
a decrease in the crystallinity of RXB and PXM and dissolution of 
RXB in molten PXM during solid dispersion preparation. In 
conclusion, dissolution enhancement of RXB was obtained by 
preparing its solid dispersions in PXM using melting technique. The 
use of a factorial design approach helped in identifying the critical 
factors in the preparation and formulation of solid dispersion. 
¾ Yogesh Rane et al.,47 (2007) have studied the dissolution rate 
enhancement efficiency and solid dispersion formation ability of 
hydrophilic swellable polymers such as sodium carboxymethyl 
cellulose (Na-CMC), sodium starch glycolate (SSG), pregelatinized 
starch (PGS), and hydroxypropylmethyl cellulose (HPMC) with 
carbamazepine using 32 full factorial design for each of the 
polymers. Solid dispersions of carbamazepine were prepared using 
solvent evaporation method with around 70% solvent recovery. The 
independent variables were the amount of polymer and organic 
solvent. The dependent variables assessed were percentage drug 
dissolved at various time points and dispersion efficiency (ie, in 
terms of particle size of solid dispersion). Solid dispersions were 
evaluated for percentage drug dissolved, wettability, differential 
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scanning calorimetry, scanning electron microscopy, and angle of 
repose. Multiple linear regression of results obtained led to 
equations, which generated contour plots to relate the dependent 
variables. 
¾ Elena Vittadini et al .,48 (2007) were carried out Gelatinization of 
tapioca starch (25% dry basis) was induced by high hydrostatic 
pressure processing (HPP) at 600 MPa under different time and 
temperature regimes (30 °C for 10, 20 and 30 min; 50 °C for 
10 min; 80 °C for 10 min). Textural, thermal and structural 
properties of the gels were studied and their stability was evaluated 
after 28 days of refrigerated (4 °C) and frozen (−18 °C) storage. 
Thermally induced gels (90 ± 1 °C, 20 min, gel-T) were used as 
controls. HPP resulted in the formation of harder gels than thermal 
processing (more significantly at lower processing temperatures) 
partially preserving the granular structure of the native starch. 
¾ Thierry Tran et al.,49 (2007) were studied the effect of starch 
chemical modifications and hydrocolloids on the proportion of 
freezable water in starch gels at various moisture contents. The 
proportion of freezable water increased with moisture content, from 
less than 6.1% to 84.9% (w/w) of the water fraction between 30% 
and 70% moisture content (wet weight basis, wwb). A transition 
between limited and excess water conditions was identified in the 
range 30-40% moisture content (wwb), whereby the proportion of 
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freezable water markedly increased from 6.1% to 40.4% (w/w) of 
the water fraction, in the case of the non-modified starch control. At 
30 and 40% moisture content (wwb), gels made of acetylated starch 
and hydroxypropylated starch had a significantly lower amount of 
freezable water than the control, in particular at 40% moisture 
content (wwb) the amount of freezable water was reduced from 
40.4% to 15.3-25.7% (w/w) of the water fraction. In systems with 
50% moisture content (wwb) or higher, modified starches did not 
show a significant reduction in freezable water compared to the 
control. Two hydrocolloids, xanthan and carboxymethyl cellulose 
(CMC) used in a 40% moisture content (wwb) starch system 
significantly reduced freezable water from 40.4% to 23.9-24.1% of 
the water fraction (w/w), at a hydrocolloid: starch ratio of 1:14 (w/w). 
The linear decrease in the freezable water proportion with xanthan 
and CMC concentration pointed to the absence of interactions 
between the starch and hydrocolloid fractions. 
¾ Nakhat PD et al.,50 (2007) were prepared silymarin-HP-β-CD solid 
dispersion and formulate to tablets in order to improve oral 
bioavailability. Tablet formulations were prepared by direct 
compression technique using superdisintegrants such as 
crosscarmellose sodium, sodium starch glycolate and polyplasdone 
XL in different concentrations. Developed formulations were 
evaluated for various pharmaceutical characteristics viz. hardness, 
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% friability, weight variation, drug content, disintegration time and in 
vitro dissolution profiles. Amongst different batches, formulations 
containing crosscarmellose sodium showed superior disintegration 
and dissolution profiles compared to other formulations. However all 
the formulations showed improved dissolution over marketed 
formulation reflecting vital role of HP-β -CD dispersion in promotion 
of silymarin oral bioavailability. Moreover, optimized formulation 
showed stability at varying temperature and relative humidity. 
¾ Murli SV et al ., 51 (2007) has been measured solid – phase axial 
dispersion in 0.15 m.i.d solid-liquid fluidized beds. The solid phase 
was ion-exchange resin in the size range of 300−1000 µm. The 
particle size distribution was measured at 34 axial locations ranging 
from 0.03 to 1.10 m from the bottom. A model describing the 
particle classification enabled the estimation of axial dispersion 
coefficient. Based on the experimental results, a correlation has 
been developed that has been found to be applicable to all the 
reported data in the published literature over a wide range of 
Reynolds number.  
¾ Mariarosa Moneghini et al.,52 (2008) have studied the application of 
attractive technique of the microwaves irradiation for the 
preparation of solvent free solid dispersions. In particular, the 
microwave technology has been considered in order to prepare an 
enhanced release dosage form for the poorly soluble drug 
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Ibuprofen (IBU), employing PVP/VA 60/40 (PVP/VA 64) and 
hydroxypropyl-β-cyclodextrin (HP-β-CD) as hydrophilic carriers. 
Their physico-chemical characteristics and dissolution properties 
were compared to the corresponding physical mixtures and the 
drug alone. The results of physico-chemical characterization 
attested a correspondence of the solid state of the drug before and 
after irradiation treatment and that an amorphous form of the drug 
was obtained. This result, together with the presence of the 
hydrophilic polymers determined a remarkable enhancement of the 
in vitro dissolution rate of the drug suggesting that the microwave 
technique could be considered as a new and interesting method to 
prepare drug–polymer systems. 
¾ Odeku OA et al., 53 (2008) have been investigated the material and 
tablet formation properties of pregelatinized (thermally modified) 
forms of four dioscorea starches. Dioscorea starches were 
pregelatinized followed by either oven drying (PS) or freeze drying 
(FD) and used as excipient in direct compression. The 
physicochemical, morphological and material properties of the 
pregelatinized starches have been investigated. The tablet 
formation properties were assessed using the 3-D modeling 
parameters, the Heckel equation and the force–displacement 
profiles. The tablet properties were evaluated using the elastic 
recovery, compactibility plots and the disintegration test. The results 
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indicate that pregelatinization improved the compressibility and 
flowability of the Dioscorea starches. The high bulk and tap 
densities of PS coupled with their good flowability offer a unique 
possibility of the starches being used as filler in capsule 
formulations. The modified starches generally showed differences 
in their time and pressure dependent deformation behaviour. PS 
exhibited higher elasticity during tableting. FD Chinese and FD 
Bitter showed higher plasticity and low fast elastic deformation than 
the PS forms of the starches indicating that the FD starches 
undergo the highest plastic deformation. 
¾ Aubin HT et al., 54 (2008) have studied the use of modified 
polysaccharides such as high amylose starch as excipients in 
controlled drug release technology.Crosslinked high amylose starch 
is a hydrophilic matrix used for the sustained release of drugs. 
Tablets using modified hybrid starch as excipient display zero-order 
release over 2–24 h. A release over 3–4 weeks was observed when 
the modified starch is used as an implant. The use of starch in 
controlled release system is appealing because it could be easily 
metabolized in the human body. We review here the use of NMR 
imaging and solid state 13C spectroscopy in the study of the various 
factors influencing drug release in such systems. 
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¾ Yongmei Xie et al., 55 (2008) were prepared solid dispersions of 
esomeprazole Zinc in polyethylene glycol 4000 ( PEG 4000 ) with 
different EZ to PEG 4000 ratios by solvent method. studies showed 
that dissolution rate of EZ were distinctively increased in the solid 
dispersion system compared to that in pure EZ or physical mixtures. 
The increase of dissolution rate was obviously related to the ratio of 
EZ to PEG4000. The solid dispersion system (EZ/PEG4000 = 1/8, 
w/w) gave the highest dissolution rate: about 14.7-fold higher than 
that of the pure EZ. EZ was proved to be in amorphous state in this 
solid dispersion by using differential scanning calorimetry (DSC) 
and scanning electron microscopy (SEM) techniques. 
¾ Biswal S et al .,56 (2008) were prepared solid dispersions of 
gliclazide with PEG 6000. The solubility of gliclazide increased with 
increasing amount of PEG 6000 in water. The SDs of gliclazide with 
PEG 6000 were prepared at 1:1, 1:2 and 1:5 (gliclazide/PEG 6000) 
ratio by melting-solvent method and solvent evaporation method. 
Evaluation of the properties of the SDs was performed by using 
dissolution, Fourier-transform infrared (FTIR) spectroscopy, 
differential scanning calorimetry (DSC) and X-ray diffraction (XRD) 
studies. The SDs of gliclazide with PEG 6000 exhibited enhanced 
dissolution rate of gliclazide, and the rate increased with increasing 
concentration of PEG 6000 in SDs. Mean dissolution time (MDT)of 
gliclazide decreased significantly after preparation of SDs and 
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physical mixture with PEG 6000. The FTIR spectroscopic studies 
showed the stability of gliclazide and absence of well-defined 
gliclazide–PEG 6000 interaction. The DSC and XRD studies 
indicated the microcrystalline or amorphous state of gliclazide in 
SDs of gliclazide with PEG 6000.  
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MATERIALS AND METHODS 
 
Table: 3 Materials used 
Name of the materials Name of company 
Etodolac  Dr.Reddys Laboratories Ltd , Hyderabad
Potato starch Loba chemie pvt.Ltd , Mumbai 
Maize starch Loba chemie pvt.Ltd , Mumbai 
Tapioca starch Loba chemie pvt.Ltd , Mumbai 
Tween 80 Qualigens fine chemicals 
Methanol Loba chemie pvt.Ltd , Mumbai 
Sodium hydroxide SD fine chem. Ltd 
Potassium dihydrogen 
phosaphate 
Ranchem Ltd 
Glacial acetic acid SD fine chem. Ltd 
Toluene Qualigens fine chemicals 
Ethanol Changshu Yangyuan chemicals 
Potassium bromide Qualigens 
Acetone Ranbaxy fine chemicals Ltd 
 
Table : 4 Equipment used 
 
Name of equipment Name of company 
Vacumm pump Gelman sciences 
Dissolution apparatus Electrolab TDT – 08L  
UV spectrometer Jasco V 530 UV spectrophotometer 
FT IR spectrometer Jasco-FT-IR 8201 PC 
pH testr 1 (water proof) Oakton instruments. 
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ANALYTICAL METHODS 
 Methods available for the identification of etodolac are 
a) Examine by infrared absorption spectrophotometry, comparing with 
 the spectrum obtained with the spectrum obtained with Etodolac 
b) Melting point: 144°C to 150°C. 
c) The retention time of the major peak in the chromatogram of the 
Assay preparation corresponds to that in the chromatogram of the 
Standard preparation, as obtained in the Assay. 
METHODS AVAILABLE FOR ESTIMATION OF ETODOLAC ARE 
a) Spectrophotometric estimation of Etodolac in pure form and 
 pharmaceutical formulation was reported. 
b) Spectrofluorimetric determination of Etodolac was reported. The 
 detection limit was reported to be 96 to 640ng/ml. 
c) The separation of Etodolac and its metabolites has been reported 
 by the use of Capillary electro – chromatography. 
d) HPLC and Mass spectrometry was reported for the determination of 
 Etodolac in human plasma. 
METHOD FOR ESTIMATION OF ETODOLAC 
 A Spectrophotometric method based on the measurement of 
absorbance at 274 nm in 0.1 M phosphate buffer pH 6.8 was used in the 
present study for estimation of Etodolac. 
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MATERIALS 
1. Etodolac pure drug. 
2. Methanol. 
3. Potassium dihydrogen phosphate. 
4. Sodium hydroxide 
5. Distilled water. 
THE METHODOLOGY USED IN THE PRESENT RESEARCH WORK 
Preparation of pH 6.8 phosphate buffer: 
 250 ml of 0.2M potassium dihydrogen phosphate in a 100 ml vessel 
and 112 ml of 0.2 M NaOH and made up to 1000 ml with water. 
Potassium dihydrogen phosphate (0.2M) 
 Dissolve 27.218 g of potassium dihydrogen phosphate in water and 
dilute to 1000 ml with water. 
Sodium hydroxide (0.2M) NaOH 
 Dissolve 8 g of NaoH in water and dilute to 1000 ml with water. 
Preparation of standard stock solution 
  Stock solutions of Etodolac were prepared by dissolving 100 mg of 
pure drug in methanol,followed by dilution to 100 ml with pH 6.8 phosphate 
buffer to obtain 1 mg/ml standard solution. 
Procedure for standard graph 
  Working solution were prepared by pipetting out 10 ml of stock 
solution, made upto 100 ml with pH 6.8 phosphate buffer to obtain  
100 mcg/ml solution. 
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 From this solution pipette out 0.4,0.8,1.2,1.6, 2,2.4, and 2.8 ml 
which were transferred into a series of 10 ml volumetric flasks and final 
volume was brought upto 10 ml with pH 6.8 phosphate buffer to get a 
concentration of 4-28 mcg/ml. Ablank was also prepared. The absorbance 
was measured at 274 nm and the standard graph was plotted against 
concentration (mcg/ml) Vs absorbance.30-35 The results were given in 
table. 5 and figure .1 
Table : 5 Standard Graph values of Etodolac in 0.1M, pH 6.8 
phosphate buffer 
Concentration µg/ml Absorbance at 274 nm 
0 0.0000 
4 0.1187 
8 0.2350 
12 0.3550 
16 0.4701 
20 0.5906 
24 0.7050 
28 0.8295 
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Fig : 1 Standard Graph of Etodolac in 0.1M, pH 6.8 phosphate buffer 
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PREPARATION AND CHARACTERIZATION OF 
SOLID DISPERSION 
                
 In the present study, pre-gelatinized starch is prepared from the 
native starches  such as Potato, Tapioca and Maize. It is low cost carrier 
widely used in pharmaceutics as diluent, binder, disintegrant and carrier 
for solid dispersion. 
Preparation of pre-gelatinized starch 
 An aqueous slurry (100 ml) of potato, Tapioca and Maize starch  
(40%) w/v containing 1% Tween-80 was heated to 65 0 C   with continuous 
stirring until the starch gelatinizes and produces a viscous translucent 
mucilage. The viscous mucilage was then dehydrated by the addition of 
acetone while stirring and the solids separated were collected by filtration 
and further dried at 400 C for 2 hrs. The dried mass obtained was crushed, 
pulverized and sifted through mesh no.120.4 
Preparation and characterization of etodolac solid dispersion 
 The prepared PGS from Potato, Tapioca and Maize are used as 
carrier in the preparation of solid dispersion of Etodolac. Etodolac is a 
member of the pyranocarboxylic acid group of drug practically in soluble in 
water. In the present study Etodolac: PGS solid dispersion are prepared at 
four different ratios namely 1:1,1:3,1:9 and 1: 19 by two different methods 
such as kneading and solvent evaporation. 
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Procedure for preparation of Etodolac solid dispersion by kneading 
method 
 Each polymer and solvent were mixed together in a mortar so as to 
obtain a homogenous paste. Etodolac was then added slowly with 
constant stirring. The mixture was then ground for 1 hour. During this 
process, an appropriate quantity of solvent was added to the mixture in 
order to maintain a suitable consistency. The paste was dried in oven at 
40°C for 24 hours. The dried complex was pulverized into a fine power.  
Procedure for preparation of Etodolac solid dispersion by solvent 
evaporation method  
 In solvent evaporation method, methanol was used as solvent and 
four different drug: carrier ratios were used (1:1, 1:3, 1:9,1:19 ) to prepare 
solid dispersion of Etodolac Respective amount of carrier was dissolved in 
required amount of methanol taken in a conical flask to get a clear 
completely soluble polymer methanol solution. Magnetic stirrer was used 
for this purpose. The weighed amount of Etodolac was added to this 
solution carefully with constant stirring. Stirring was continued until the 
drug was completely incorporated in solvent. Then the solvent was 
removed by evaporation at 40° C under vacuum. The mass obtained was 
dried crushed, pulverized and shifted through mesh no. 80. 
Physical mixture (PM) 
 Drug: Carrier ratio of 1:1 was used to prepare physical mixture 
(1000 mg of drug and 1000 mg of carrier). The drug and carrier were 
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mixed thoroughly in a mortar. This was done by geometric dilution 
technique to ensure homogenous distribution. 
Table : 6  Drug carrier ratio and respective amount taken: 
 
CHARACTERIZATION AND EVALUATION OF  ETODOLAC  SOLID 
DISPERSION 
 The prepared Etodolac :PGS solid dispersion were characterized 
and evaluated for:-  
a. Thin layer Chromatography 
b. IR spectral Analysis 
c. Powdered  X-ray Diffraction studies 
d. Differential Scanning Calorimetry 
e. Scanning Electron Microscopy 
f. Drug content uniformity 
g. Invitro dissolution studies 
Thin layer chromatography (TLC) 
 A thin layer chromatographic method was also carried to study the 
interaction between the drug and carriers and also to confirm the chemical 
Drug carrier ratio Drug (mg) Carrier (mg) 
1:1 1000 1000 
1:3 500 1500 
1:9 200 1800 
1:19 100 1900 
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satiability of the solid dispersions prepared. For this, the pure drug and the 
solid dispersions prepared with various carriers by kneading and  solvent 
evaporation method were subjected to chromatographic studies.  
The TLC system used for this study is given below. 
Precoated TLC Plates :   Manufactured by SD Fine chemicals Ltd,  
  Mumbai 
Adsorbent Layer :  Silicagel GF 254. 
Layer Thickness :  250 µm 
Size                                   :   10 ×10 cm 
Separation technique :  Ascending 
Chamber Saturation :  The chamber was lined on three sides with 
filter paper and saturated for 30 minutes.        
Mobile phase :   glacial acetic  acid : ethanol: toluene [ 0.5: 30: 
70 % v/v] 
Preparation of sample :  A suitable amount of pure drug or equivalent 
solid dispersion dissolved in  acetone and 
dilute to 10 ml with the same solvent and  
used for spotting. 
Amount applied :  10 µl.  
Detection : Under UV light at 254nm. 31 
 The Rf values obtained were given in the table.7-8 and thin layer 
chromatograms of  pure drug avd various solid dispersions were shown in  
fig.2. 
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Table : 7 TLC data for pure drug and various solid dispersion 
systems ( kneading method ) 
 
Pure drug Polymer Ratio Rf  Value 
Etodolac - - 0.49 
Etodolac PGS(Potato) 1:1 0.40 
Etodolac PGS(Tapioca) 1:1 0.40 
Etodolac PGS(Maize) 1:1 0.40 
 
Table : 8 TLC data for pure drug and various solid dispersion 
systems ( solvent evaporation method ) 
 
Pure drug Polymer Ratio Rf  Value 
Etodolac - - 0.49 
Etodolac PGS(Potato) 1:1 0.60 
Etodolac PGS(Tapioca) 1:1 0.60 
Etodolac PGS(Maize) 1:1 0.60 
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Fig : 2 Thin Lay chromatogram of Pure Drug Etodolac and Solid 
dispersion by kneading and solvent  evaporation method. (1:1) ratio 
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 IR Spectral analysis:  
 Fourier Transform (FTIR) spectra of the samples were obtained in 
the range of 400-4000 cm-1 using a Jasco-FT-IR 8201 PC 
Spectrophotometer (Jasco. Essex) by the KBr disc method.36 The IR 
Spectra obtained are given in fig. 3-12 
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Fig : 3   IR Spectrum Of Pure Drug Etodolac 
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Fig: 4 IR Spectrum of  PGS( Potato ) 
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Fig: 5 IR spectrum of  PGS ( Tapioca) 
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Fig: 6 IR spectrum of PGS( Maize) 
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Fig: 7 IR spectrum of solid dispersion of Etodolac with  PGS ( Potato) (1: 1) KM 
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Fig: 8 IR spectrum of solid dispersion of Etodolac with  PGS( Tapioca)  (1: 1) KM  
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Fig: 9 IR spectrum of solid dispersion of Etodolac with  PGS( Maize) (1: 1) KM  
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  Fig: 10  IR spectrum of solid dispersion of Etodolac with  PGS( Potato )  (1: 1) SE  
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Fig: 11  IR spectrum of solid dispersion of Etodolac with  PGS ( Tapioca) (1: 1) SE   
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Fig: 12  IR spectrum of solid dispersion of Etodolac with  PGS( Maize) (1: 1) SE  
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Powder X-ray diffractometry 
 The Powder X-ray Diffraction Patterns were recorded using Bruker 
AXS D8 Advance model  with Cu as anode material and crystal graphite 
monochromator,wavelength 1.5406A0 operated at a voltage of 40 kV and a 
current of 30 mA. The samples were analyzed in the 2θ angle range of  
3° to 65° and the process parameters were set as follows: step size of 
0.45° (2θ), scan step time of 0.1 seconds and time of acquisition of 
 2 hours. The results were shown in fig. 13-19. 
 
Fig: 13  X- ray diffraction studies of pure Etodolac 
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Fig:  14  X-ray diffraction studies of solid dispersion of Etodolac with   
PGS( Potato )  (1: 1) KM 
 
 
 
Fig : 15  X-ray diffraction studies  of solid dispersion of Etodolac with   
PGS ( Tapioca) (1: 1) KM 
 
Preparation & Characterization of Solid Dispersion 
 73
Fig: 16 X-ray diffraction studies of solid dispersion of Etodolac with   
PGS( Maize) (1: 1) KM 
 
Fig: 17  X-ray diffraction studies of solid dispersion of Etodolac with   
PGS( Potato )  (1: 1) SE 
 
 
 
 
Preparation & Characterization of Solid Dispersion 
 74
Fig: 18 X-ray diffraction studies of solid dispersion of Etodolac with   
PGS ( Tapioca) (1: 1) SE 
 
Fig: 19 X-ray diffraction studies of solid dispersion of Etodolac with   
PGS( Maize) (1: 1) SE 
 
 
Preparation & Characterization of Solid Dispersion 
 75
Differential Scanning Calorimetry 
 The DSC measurements were performed using a Mettleer Toledo 
DSC 822e model controlled by STARe Software (Mettler – Toledo. GmbH, 
Switzerland). All accurately weighted samples (1 mg of aceclofenac or its 
equivalent) were placed in seated aluminum pans, before heating under 
nitrogen flow (20ml/min) at a scanning rate of 10° C min-1, over the 
temperature range of 30°C to 220°C. An empty aluminum pan was used 
as reference. The results were shown in fig.20-26. 
Fig: 20 DSC thermogram of pure Etodolac 
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Fig: 21 DSC thermogram  of solid dispersion of Etodolac with  PGS 
( Potato )  (1: 1) KM 
 
Fig: 22 DSC thermogram of solid dispersion of Etodolac with   
PGS ( Tapioca) (1: 1) KM 
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Fig: 23 DSC thermogram of solid dispersion of Etodolac with   
PGS( Maize) (1: 1) KM 
 
 
Fig: 24 DSC thermogram of solid dispersion of Etodolac with   
PGS( Potato )  (1: 1) SE 
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Fig: 25 DSC thermogram of solid dispersion of Etodolac with   
PGS ( Tapioca) (1: 1) SE  
 
Fig: 26 DSC thermogram of solid dispersion of Etodolac with  PGS( 
Maize) (1: 1) SE 
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Scanning Electron Microscopy 
         Particle surface of the prepared solid dispersion were analysed by 
JSM-6390 instrument.The instrument was operated at a voltage of 20 
kV.For pure drug and various solid dispersions the particle surface were 
observed in the following Fig 27-30. 
 
Fig: 27 Scanning Electron Microscopy of Pure drug Etodolac at 
5000X 
 
Fig : 28 Scanning Electron Microscopy of Pure drug Etodolac at 
10,000X 
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Fig:29 Scanning Electron Microscopy of Etodolac:  PGS( Potato)  
Solid dispersion ( 1:19 ) KM at 5000X 
 
 
Fig : 30 Scanning Electron Microscopy of Etodolac:  PGS( Potato )  
Solid dispersion ( 1:19 ) KM at 10,000X 
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Drug Content uniformity         
 The prepared Etodolac solid dispersion  was tested for drug content 
uniformity. From each bach of solid dispersion prepared in different 
ratios,equivalent to 100 mg of Etodolac solid dispersion were taken and 
analyzed for drug content uniformity. 
Estimation of Etodolac  in solid dispersion by UV Spectroscopy:    
    Accurately weighed amount of solid dispersion was dissolved in 100 
ml of pH 6.8 phosphate buffer in 100 ml volumetric flask which was 
previously clean and dry. This solution after suitable dilution was 
measured for absorbance at 274 nm in a Jasco V530 UV visible 
spectrophotometer. The results were shown in table.9,10. 
Table : 9 Drug Content Uniformity in solid dispersions  
( Kneading method ) 
 
Solid 
dispersion 
Drug: 
Carrier 
Amount of 
S.D taken 
(mg) 
Expected 
Amount of 
Etodolac in 
S.D(mg) 
Etodolac estimated 
by 
spectrophotometer 
(%) 
1:1 200 100 97.8 
1:3 400 100 101.0 
1:9 1000 100 100.8 
Etodolac: 
PGS(Potato) 
1:19 2000 100 97.8 
1:1 200 100 93.0 
1:3 400 100 94.4 
1:9 1000 100 102.8 
Etodolac  
PGS(Tapioca) 
1:19 2000 100 99.8 
1:1 200 100 98.6 
1:3 400 100 96.2 
1:9 1000 100 93.3 
Etodolac: 
PGS (Maize) 
1:19 2000 100 97.8 
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Table :10 Drug Content Uniformity in solid dispersions  
( solvent evaporation method ) 
Solid dispersion Drug:Carrier
Amount of 
S.D 
taken(mg) 
Expected 
Amount 
of 
Etodolac 
in 
S.D(mg) 
Etodolac 
estimated by 
spectrophoto
meter(%) 
1:1 200 100 94.8 
1:3 400 100 97.3 
1:9 1000 100 95.6 
Etodolac: 
PGS(Potato) 
1:19 2000 100 95.2 
1:1 200 100 100.0 
1:3 400 100 95.1 
1:9 1000 100 93.6 
Etodolac: 
PGS(Tapioca) 
1:19 2000 100 98.8 
1:1 200 100 98.4 
1:3 400 100 94.8 
1:9 1000 100 96.2 
Etodolac: 
PGS (Maize) 
1:19 2000 100 99.5 
 
In-vitro dissolution studies 
 The dissolution studies are the most important part of the evaluation 
of solid dispersion, where the dissolution of pure drug and solid dispersion 
is carried out. Dissolution rate studies of various solid dispersions were 
carried out in phosphate buffer of PH 6.8 using USP XXII dissolution 
apparatus (Electro lab). 
Dissolution method 
 900 ml of phosphate buffer of PH 6.8 was used as dissolution 
medium. SDs equivalent to 100 mg of Etodolac  was taken in a hard 
gelatin capsule; a stainless steel wire was wound around the capsule to 
sink. The paddle type stirrer was adjusted to 100 rpm. The temperature 
was maintained at 37°±0.5°c. 10 ml aliquot dissolution media was 
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withdrawn at different time intervals and volume withdrawn was replaced 
with fresh quantity of dissolution medium. The samples were analyzed for 
Etodolac after suitable dilution by measuring the absorption values at 274 
nm using Jasco V 530 UV visible spectrophotometer. Phosphate buffer of 
pH 6.8 used as a blank. The percentage of Etodolac  dissolved at various 
time intervals was calculated and plotted against time. T50, T90 values were 
calculated from these dissolution curves.31,37 The results are shown in 
table.11-16 and fig. 32-37.   
 
Fig: 31  Dissolution apparatus 
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Table: 11 Dissolution Profile of  Etodolac from PGS( Potato)  solid 
dispersion at different drug carrier ratios ( kneading method ) 
Percentage release of Etodolac from different drug carrier 
ratios 
Time in 
minutes Pure 
drug 
100 mg 
Physical 
mixture 1:1 1:3 1:9 1:19 
0 0 0 0 0 0 0 
5 1.48 1.50 1.52 1.54 1.67 1.99 
10 2.99 3.65 3.78 3.69 3.86 3.91 
15 4.01 7.49 8.51 9.61 10.25 15.95 
30 7.37 15.61 20.97 24.68 34.35 36.40 
45 17.39 27.13 63.86 67.83 76.91 86.15 
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Fig: 32   Dissolution Profile of  Etodolac from PGS( Potato)  solid 
dispersion at different drug carrier ratios ( kneading method ) 
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Table:12  Dissolution Profile of  Etodolac from PGS(Tapioca)  solid 
dispersion at different drug carrier ratios ( kneading method ) 
 
Percentage release of Etodolac from different drug carrier 
ratios 
Time in 
minutes Pure 
drug 
100 mg 
Physical 
mixture 1:1 1:3 1:9 1:19 
0 0 0 0 0 0 0 
5 1.48 1.63 1.71 1.83 1.91 1.96 
10 2.99 3.01 3.52 3.58 4.01 4.12 
15 4.01 6.54 7.41 8.01 8.53 8.71 
30 7.37 14.23 20.23 21.45 20.83 24.05 
45 17.39 25.15 55.86 60.45 62.93 76.01 
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Fig: 33   Dissolution Profile of  Etodolac from PGS(Tapioca)  solid 
dispersion at different drug carrier ratios ( kneading method ) 
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Table : 13 Dissolution Profile of  Etodolac from PGS(Maize)  solid 
dispersion at different drug carrier ratios ( kneading method ) 
 
Percentage release of Etodolac from different drug carrier 
ratios 
Time in 
minutes Pure 
drug 
100 mg 
Physical 
mixture 1:1 1:3 1:9 1:19 
0 0 0 0 0 0 0 
5 1.48 1.81 1.91 1.91 1.97 1.98 
10 2.99 3.51 3.61 3.72 3.89 3.96 
15 4.01 5.85 6.41 7.43 8.59 10.05 
30 7.37 17.21 19.25 20.31 21.76 25.48 
45 17.39 28.31 44.58 58.51 59.48 75.99 
 
0
10
20
30
40
50
60
70
80
0 5 10 15 20 25 30 35 40 45 50
Time in Minutes
Pe
rc
en
ta
ge
 R
el
ea
se
Pure Drug 100 mg Physical Mixture 1:01 1:03 1:09 1:19  
Fig: 34  Dissolution Profile of  Etodolac from PGS(Maize)  solid 
dispersion at different drug carrier ratios ( kneading method ) 
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Table : 14 Dissolution Profile of  Etodolac from PGS(Potato)  solid 
dispersion at different drug carrier ratios ( solvent evaporation  
method ) 
Percentage release of Etodolac from different drug carrier 
ratios 
Time in 
minutes Pure 
drug 
100 mg 
Physical 
mixture 1:1 1:3 1:9 1:19 
0 0 0 0 0 0 0 
5 1.48 1.50 1.51 1.53 1.64 1.89 
10 2.99 3.65 3.79 4.01 4.18 4.29 
15 4.01 7.49 7.99 8.03 8.99 9.23 
30 7.37 15.61 19.98 22.09 24.95 25.09 
45 17.39 27.13 47.89 58.87 74.98 83.17 
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Fig: 35 Dissolution Profile of  Etodolac from PGS(Potato)  solid 
dispersion at different drug carrier ratios ( solvent evaporation  
method ) 
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Table: 15 Dissolution Profile of  Etodolac from PGS(Tapioca)  solid 
dispersion at different drug carrier ratios ( solvent evaporation  
method ) 
Percentage release of Etodolac from different drug carrier 
ratios 
Time in 
minutes Pure 
drug 
100 mg 
Physical 
mixture 1:1 1:3 1:9 1:19 
0 0 0 0 0 0 0 
5 1.48 1.63 1.69 1.73 1.74 1.81 
10 2.99 3.01 3.41 3.50 3.89 3.90 
15 4.01 6.54 6.94 7.57 8.18 8.19 
30 7.37 14.23 22.25 23.68 26.25 27.34 
45 17.39 25.15 49.03 63.68 72.58 77.51 
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Fig: 36  Dissolution Profile of  Etodolac from PGS(Tapioca)  solid 
dispersion at different drug carrier ratios ( solvent evaporation  
method ) 
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Table: 16 Dissolution Profile of  Etodolac from PGS(Maize) solid 
dispersion at different drug carrier ratios ( solvent evaporation  
method ) 
Percentage release of Etodolac from different drug carrier 
ratios 
Time in 
minutes Pure 
drug 
100 mg 
Physical 
mixture 1:1 1:3 1:9 1:19 
0 0 0 0 0 0 0 
5 1.48 1.81 1.95 1.96 1.96 1.98 
10 2.99 3.51 3.53 3.51 3.54 3.60 
15 4.01 5.85 5.99 6.03 7.12 7.35 
30 7.37 17.21 17.91 20.15 23.49 29.05 
45 17.39 28.31 51.05 63.94 70.47 75.35 
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Fig: 37 Dissolution Profile of  Etodolac from PGS(Maize) solid 
dispersion at different drug carrier ratios 
 ( solvent evaporation  method ) 
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Table : 17 Percentage release of  Etodolac from various solid dispersions ( kneading method ) 
 
Percentage release of Etodolac from 
PGS(Potato) PGS(Tapioca) PGS(Maize) Time in minutes Pure 
drug 1:1 1:3 1:9 1:19 1:1 1:3 1:9 1:19 1:1 1:3 1:9 1:19 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 
5 1.48 1.52 1.54 1.67 1.99 1.71 1.83 1.91 1.96 1.91 1.91 1.97 1.98 
10 2.99 3.78 3.69 3.86 3.91 3.52 3.58 4.01 4.12 3.61 3.72 3.89 3.96 
15 4.01 8.51 9.61 10.25 15.95 7.41 8.01 8.53 8.71 6.41 7.43 8.59 10.05 
30 7.37 20.97 24.68 34.35 36.40 20.23 21.45 20.83 24.05 19.25 20.31 21.76 25.48 
45 17.39 63.86 67.83 76.91 86.15 55.86 60.45 62.93 76.01 44.58 58.51 59.48 75.99 
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Table : 18 Percentage release of  Etodolac from various solid dispersions ( solvent evaporation method ) 
 
Percentage release of Etodolac from 
PGS(Potato) PGS(Tapioca) PGS(Maize) 
Time in 
minutes 
 
Pure 
drug 1:1 1:3 1:9 1:19 1:1 1:3 1:9 1:19 1:1 1:3 1:9 1:19 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 
5 1.48 1.51 1.53 1.64 1.89 1.69 1.73 1.74 1.81 1.95 1.96 1.96 1.98 
10 2.99 3.79 4.01 4.18 4.29 3.41 3.50 3.89 3.90 3.53 3.51 3.54 3.60 
15 4.01 7.99 8.03 8.99 9.23 6.94 7.57 8.18 8.19 5.99 6.03 7.12 7.35 
30 7.37 19.98 22.09 24.95 25.09 22.25 23.68 26.25 27.34 17.91 20.15 23.49 29.05 
45 17.39 47.89 58.87 74.98 83.17 49.03 63.68 72.58 77.51 51.05 63.94 70.47 75.35 
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Table:19 Relation between % carrier and T50, T90 values for 
Etodolac:PGS(Potato)  solid dispersions 
 
T50 (min) T90 (min) 
% of drug %of carrier KM SE KM SE 
1 1 40.25 - - - 
1 3 38.00 41.00 - - 
1 9 34.75 37.75 - - 
1 19 33.25 35.75 - - 
 
Table:20  Relation between % carrier and T50, T90 values for 
Etodolac:PGS(Tapioca)  solid dispersions 
 
T50 (min) T90 (min) 
% of drug %of carrier KM SE KM SE 
1 1 42.50 - - - 
1 3 41.00 40.00 - - 
1 9 40.00 38.00 - - 
1 19 37.50 37.00 - - 
 
Table: 21  Relation between % carrier and T50, T90 values for 
Etodolac:PGS(Maize) solid dispersions: 
 
T50 (min) T90 (min) 
% of drug % of carrier KM SE KM SE 
1 1 - 44.50 - - 
1 3 41.50 40.25 - - 
1 9 41.25 38.50 - - 
1 19 37.50 37.00 - - 
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Table : 22 Percentage Etodolac undissolved from pure form and from 
PGS (Potato) solid dispersions at various  drug carrier ratios  
( kneading method ) 
Percentage  Etodolac undissolved  from ( log percentage 
Etodolac undissolved ) Time in 
minutes Pure drug 
100 mg 
Physical 
mixture 1:1 1:3 1:9 1:19 
0 100 ( 2.0 ) 
100 
( 2.0 ) 
100 
( 2.0 ) 
100 
( 2.0 ) 
100 
( 2.0 ) 
100 
( 2.0 ) 
5 98.52 (1.9935) 
98.5 
(1.9934) 
98.48 
(1.9933)
98.46 
(1.9932)
98.33 
(1.9926) 
98.01 
(1.9912)
10 97.01 (1.9868) 
96.35 
(1.9838) 
96.22 
(1.9832)
96.31 
(1.9836)
96.14 
(1.9829) 
96.09 
(1.9826)
15 95.99 (1.9822) 
92.51 
(1.9661) 
91.49 
(1.9613)
90.39 
(1.9561)
89.75 
(1.9530) 
84.05 
(1.9245)
30 92.63 (1.9667) 
84.39 
(1.9262) 
79.03 
(1.8977)
75.32 
(1.8769)
65.65 
(1.8172) 
63.60 
(1.8034)
45 82.61 (1.9170) 
72.87 
(1.8625) 
36.14 
(1.5579)
32.17 
(1.5074)
23.09 
(1.3634) 
13.85 
(1.1414)
 
Fig: 38  Percentage Etodolac undissolved from pure form and from 
PGS (Potato) solid dispersions at various  drug carrier ratios  
( kneading method ) 
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Table : 23 Percentage Etodolac undissolved from pure form and from 
PGS (Tapioca) solid dispersions at various  drug carrier ratios  
( kneading method ) 
Percentage  Etodolac undissolved  from ( log percentage 
Etodolac undissolved ) Time in 
minutes Pure drug 
100 mg 
Physical 
mixture 1:1 1:3 1:9 1:19 
0 100 ( 2.0 ) 
100 
( 2.0 ) 
100 
( 2.0 ) 
100 
( 2.0 ) 
100 
( 2.0 ) 
100 
( 2.0 ) 
5 98.52 (1.9935) 
98.37 
(1.9928) 
98.29 
(1.9925)
98.17 
(1.9919)
98.09 
(1.9916) 
98.04 
(1.9914)
10 97.01 (1.9868) 
96.99 
(1.9867) 
96.48 
(1.9844)
96.42 
(1.9841)
95.99 
(1.9822) 
95.88 
(1.9817)
15 95.99 (1.9822) 
93.46 
(1.9706) 
92.59 
(1.9665)
91.99 
(1.9637)
91.47 
(1.9612) 
91.29 
(1.9604)
30 92.63 (1.9667) 
85.77 
(1.9333) 
79.77 
(1.9018)
78.55 
(1.8951)
79.17 
(1.8985) 
75.95 
(1.8805)
45 82.61 (1.9170) 
74.85 
(1.8741) 
44.14 
(1.6448)
39.55 
(1.5971)
37.07 
(1.5690) 
23.99 
(1.3800)
 
Fig: 39   Percentage Etodolac undissolved from pure form and 
from PGS (Tapioca) solid dispersions at various  drug carrier ratios  
( kneading method ) 
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Table :24 Percentage Etodolac undissolved from pure form and from 
PGS( Maize) solid dispersions at various  drug carrier ratios 
 ( kneading method ) 
Percentage  Etodolac undissolved  from ( log percentage 
Etodolac undissolved ) Time in 
minutes Pure drug 
100 mg 
Physical 
mixture 1:1 1:3 1:9 1:19 
0 100 ( 2.0 ) 
100 
( 2.0 ) 
100 
( 2.0 ) 
100 
( 2.0 ) 
100 
( 2.0 ) 
100 
( 2.0 ) 
5 98.52 (1.9935) 
98.19 
(1.9920) 
98.09 
(1.9916)
98.09 
(1.9916)
98.03 
(1.9913) 
98.02 
(1.9913)
10 97.01 (1.9868) 
96.49 
(1.9844) 
96.39 
(1.9840)
96.28 
(1.9835)
96.11 
(1.9827) 
96.04 
(1.9824)
15 95.99 (1.9822) 
94.15 
(1.9738) 
93.59 
(1.9712)
92.57 
(1.9664)
91.41 
(1.9609) 
89.95 
(1.9540)
30 92.63 (1.9667) 
82.79 
(1.9179) 
80.75 
(1.9071)
79.69 
(1.9014)
78.24 
(1.8934) 
74.52 
(1.8722)
45 82.61 (1.9170) 
71.69 
(1.8554) 
55.42 
(1.7436)
41.49 
(1.6179)
40.52 
(1.6076) 
24.01 
(1.3803)
Fig: 40 Percentage Etodolac undissolved from pure form and from 
PGS( Maize) solid dispersions at various  drug carrier ratios  
( kneading method ) 
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Table :25 Percentage Etodolac undissolved from pure form and from 
PGS (Potato) solid dispersions at various  drug carrier ratios 
( solvent evaporation method ) 
Percentage  Etodolac undissolved  from ( log percentage 
Etodolac undissolved ) Time in 
minutes Pure drug 
100 mg 
Physical 
mixture 1:1 1:3 1:9 1:19 
0 100 ( 2.0 ) 
100 
( 2.0 ) 
100 
( 2.0 ) 
100 
( 2.0 ) 
100 
( 2.0 ) 
100 
( 2.0 ) 
5 98.52 (1.9935) 
98.5 
(1.9934) 
98.49 
(1.9933)
98.47 
(1.9933)
98.36 
(1.9928) 
98.11 
(1.9917)
10 97.01 (1.9868) 
96.35 
(1.9838) 
96.21 
(1.9832)
95.99 
(1.9822)
95.82 
(1.9814) 
95.71 
(1.9809)
15 95.99 (1.9822) 
92.51 
(1.9661) 
92.01 
(1.9638)
91.97 
(1.9636)
91.01 
(1.9590) 
90.77 
(1.9579)
30 92.63 (1.9667) 
84.39 
(1.9262) 
80.02 
(1.9031)
77.91 
(1.8915)
75.05 
(1.8753) 
74.91 
(1.8745)
45 82.61 (1.9170) 
72.87 
(1.8625) 
52.11 
(1.7169)
41.13 
(1.6141)
25.02 
(1.3982) 
16.83 
(1.2260)
 
Fig: 41 Percentage Etodolac undissolved from pure form and from 
PGS (Potato) solid dispersions at various  drug carrier ratios 
( solvent evaporation method) 
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Table : 26 Percentage Etodolac undissolved from pure form and from 
PGS (Tapioca) solid dispersions at various  drug carrier ratios  
( solvent evaporation  method ) 
Percentage  Etodolac undissolved  from ( log percentage 
Etodolac undissolved ) Time in 
minutes Pure drug 
100 mg 
Physical 
mixture 1:1 1:3 1:9 1:19 
0 100 ( 2.0 ) 
100 
( 2.0 ) 
100 
( 2.0 ) 
100 
( 2.0 ) 
100 
( 2.0 ) 
100 
( 2.0 ) 
5 98.52 (1.9935) 
98.37 
(1.9928) 
98.31 
(1.9925)
98.27 
(1.9924)
98.26 
(1.9923) 
98.19 
(1.9920)
10 97.01 (1.9868) 
96.99 
(1.9867) 
96.59 
(1.9849)
96.50 
(1.9845)
96.11 
(1.9827) 
96.10 
(1.9827)
15 95.99 (1.9822) 
93.46 
(1.9706) 
93.06 
(1.9687)
92.43 
(1.9658)
91.82 
(1.9629) 
91.81 
(1.9628)
30 92.63 (1.9667) 
85.77 
(1.9333) 
77.75 
(1.8907)
76.32 
(1.8826)
73.75 
(1.8677) 
72.66 
(1.8612)
45 82.61 (1.9170) 
74.85 
(1.8741) 
50.97 
(1.7073)
36.32 
(1.5601)
27.42 
(1.4380) 
22.49 
(1.3519)
Fig: 42 Percentage Etodolac undissolved from pure form and from 
PGS (Tapioca) solid dispersions at various  drug carrier ratios  
( solvent evaporation  method ) 
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Table : 27 Percentage Etodolac undissolved from pure form and from 
PGS( Maize) solid dispersions at various  drug carrier ratios ( solvent 
evaporation  method ) 
Percentage  Etodolac undissolved  from ( log percentage 
Etodolac undissolved ) Time in 
minutes Pure drug 
100 mg 
Physical 
mixture 1:1 1:3 1:9 1:19 
0 100 ( 2.0 ) 
100 
( 2.0 ) 
100 
( 2.0 ) 
100 
( 2.0 ) 
100 
( 2.0 ) 
100 
( 2.0 ) 
5 98.52 (1.9935) 
98.19 
(1.9920) 
98.05 
(1.9914)
98.04 
(1.9914)
98.04 
(1.9914) 
98.02 
(1.9913)
10 97.01 (1.9868) 
96.49 
(1.9844) 
96.47 
(1.9843)
96.49 
(1.9844)
96.46 
(1.9843) 
96.40 
(1.9840)
15 95.99 (1.9822) 
94.15 
(1.9738) 
94.01 
(1.9731)
93.97 
(1.9729)
92.88 
(1.9679) 
92.65 
(1.9668)
30 92.63 (1.9667) 
82.79 
(1.9179) 
82.09 
(1.9142)
79.85 
(1.9022)
76.51 
(1.8837) 
70.95 
(1.8509)
45 82.61 (1.9170) 
71.69 
(1.8554) 
48.95 
(1.6897)
36.06 
(1.5570)
29.53 
(1.4702) 
24.65 
(1.3918)
 
Fig: 43 Percentage Etodolac undissolved from pure form and from 
PGS( Maize) solid dispersions at various  drug carrier ratios ( solvent 
evaporation  method) 
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Table : 28  First order  rate constant for Etodolac dissolution from 
various solid dispersions 
 
K ( min -1 ) 
Sample 
KM SE 
Pure drug 0.0050 
Physical mixture  
ETD: PGS(Potato) 0.0060 
ETD:PGS(Tapioca) 0.0100 
ETD: PGS(Maize) 0.0053 
Solid dispersion  
ETD: PGS( Potato)   
1:1 0.0233 0.0125 
1:3 0.0250 0.0184 
1:9 0.0300 0.0350 
1:19 0.0454 0.0416 
ETD: PGS(Tapioca)   
1:1 0.0181 0.0130 
1:3 0.0194 0.0208 
1:9 0.0233 0.0291 
1:19 0.0333 0.0333 
ETD: PGS(Maize)   
1:1 0.0119 0.0145 
1:3 0.0194 0.0233 
1:9 0.0197 0.0250 
1:19 0.0300 0.0333 
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RESULTS AND DISCUSSION 
 Solid dispersion of Etodolac  were prepared by depositing  on the 
polymers namely PGS (Potato), PGS (Tapioca)  and PGS( Maize) by 
solvent evaporation method and kneading method. Solid dispersions at 
different drug: carrier ratios (1:1, 1:3, 1:9, 1:19 ) were prepared . All solid 
dispersions prepared were found to be fine and free flowing powders. The 
percent of drug content in the solid dispersions were given in table 9,10. 
There was no significant loss of drug during the preparation of solid 
dispersions and the proportion of drug and carrier remained the same as 
that initially taken. The estimated drug content of the prepared solid 
dispersions was in the range of 100±7%.  
 The prepared  solid dispersions were characterized by TLC, FTIR, 
X-ray diffraction, Scanning Electron Microscopy and Differential Scanning 
Calorimetry    
Thin Layer Chromatography 
 In TLC studies, Etodolac dispersed in various carriers showed the 
same Rf  value as pure compound and no additional spots were detected. 
TLC studies thus indicated no interaction between Etodolac and carriers in 
the solid dispersions prepared. This observation also indicated that 
Etodolac was not decomposed during the preparation of solid dispersions. 
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FT-IR Spectral Analysis 
 Compatibility studies of Etodolac and the carriers PGS (Potato), 
PGS (Tapioca) and PGS( Maize) were carried out by using FT-IR. The IR 
spectra obtained are given in fig 2-11. In Etodolac IR spectrum, intense 
peaks were noticed at 1746 cm-1  ( – C=O stretching ),1412 cm-1 ( – NH 
bending ), 1034 cm -1 ( C–O stretching ) and 748 cm -1 ( monosubstituted 
benzene ). 
 IR spectra of Etodolac and its solid dispersions are identical. The 
principal IR absorption peaks of Etodolac were all observed in the spectra 
of Etodolac  as well as its dispersions. IR spectra indicated no interaction 
between Etodolac and carriers in the solid dispersions. 
Powder X- Ray Diffraction  
 The X-ray diffraction pattern of pure drug Etodolac showed a 
numerous distinctive peaks indicating a high crystallinity. Diffraction 
pattern of solid dispersions showed reduction in intensive peaks .This 
indicates conformation of changing the nature of the compound from 
crystalline to amorphous nature shown in fig:13-19.   
Differential Scanning Calorimetry  
         The  thermal behaviour of solid dispersions of Etodolac with PGS 
prepared from Potato, Tapioca and Maize at 1:1 ratio prepared by 
kneading and solvent evaporation method was studied using DSC to 
confirm the formation of solid complexes are shown in fig:20-26.The DSC 
thermogram of pure drug Etodolac exhibited an endothermic peak at 
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150.660C  corresponding to its melting point. The two peaks in the 
thermogram is due to different polymorphic form of the drug. For solid 
dispersion systems such as ETD:PGS(Potato) KM, ETD: PGS (Tapioca) 
KM, ETD: PGS (Maize) KM, ETD: PGS(Potato) SE, ETD: PGS (Tapioca) 
SE and ETD: PGS(Maize) SE at 1:1 ratio this peaks are at 149.550C , 
149.420C, 149.160C,150.100C,150.090C and 149.470C respectively. A 
reduction in intensity of endothermic peak is observed in all solid 
dispersions indicative of amorphous change from crystallinity. 
Furthermore, the characteristic endothermic peak is slightly shifted to 
lower temperature, indicating that there is no interaction between drug and 
carrier. 
Scanning Electron Microscopy 
   Needle shaped crystals were clearly evident from scanning 
electron microscopy of pure drug indicating high crystallinity of the active 
moiety under 5000X and 10,000X magnification shown in fig:29-30.Under 
same magnifications it was found that the surface of the solid dispersion of 
drug and PGS(Potato) at 1:19 ratio prepared by kneading method were 
seen as swollen fragmented particles. Resulted picture has been shown in 
fig : 27-30. 
Results & Discussion 
 103
In- vitro dissolution Studies  
 The dissolution profiles of pure drug, physical mixture and various 
solid dispersions were given in table11-16 . and fig. 32-37 The dissolution 
parameters of T50 and dissolution rate indicates rapid dissolution of 
Etodolac  from the solid dispersions when compared with the pure drug  
and physical mixture as the proportion of the polymer in the dispersion 
was increased the dissolution rate of Etodolac also increased. T50 values 
were found to be decreased and K values found to be increased when the 
carrier concentration was raised indicating the fast dissolution of Etodolac 
at higher carrier concentration. Among the solid dispersions prepared 
Etodolac: PGS( Potato) (1:19)  KM dispersions gave the highest 
dissolution rate.  
 The order of dissolution of Etodolac from various carriers is `PGS 
(Potato) KM > PGS (Potato) SE> PGS (Tapioca) SE> PGS (Tapioca) KM> 
PGS( Maize) KM> PGS( Maize )SE. 
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FORMULATION STUDIES ON SELECTED 
SOLID DISPERSION OF ETODOLAC 
 
Tablets may be defined as solid pharmaceutical dosage 
forms containing drug substance with or without suitable 
diluents, prepared by either compression or molding. 
Formulation of tablets 
Etodolac solid dispersion in PGS( Potato) at a drug carrier 
ratio of 1:19 were formulated into tablets with usual additives 
and evaluated for drug release characteristics. Tablets 
containing 30 mg of Etodolac  were prepared using the solid 
dispersions and other additives as per the formula given in 
table.29 . 
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Table : 29  Formula of Etodolac tablets 
S.No Ingredients Formulations  ( mgs) 
1 Etodolac-Potato PGS 
(1:19)(KM) 
600 
2 Microcrystalline cellulose 70.0 
3 Povidone 12.5 
4 Colloidal silicon dioxide 7.00 
5 Magnesium stearate 10.5 
 
Table: 30  Materials used for tablet formulation: 
Name of the materials Name of company 
Etodolac: Potato PGS 
(1:19) drug carrier ratio. Prepared in the laboratory 
Etodolac Dr. Reddy
,s Laboratories Ltd, 
Hyderabad 
Povidone SD Fine chemicals Ltd, Mumbai. 
Micro crystalline cellulose Loba chemie, Mumbai 
Colloidal silicon dioxide Himedia Laboratories Pvt Ltd 
Magnesium stearate SD Fine chemicals Ltd, Mumbai. 
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Table: 31  Equipments used for tablet formulation 
Name of equipment Name of company 
Tablet punching machine  Rimek Mini Press 1 
Tablet disintegration test 
apparatus   
Remi equipments  
Pfizer tablet hardness tester  Scientific engineering 
corporation  
Roche friability tester  Remi equipments 
Dissolution apparatus Electrolab  TDT – 08L          
UV spectrometer Jasco V 530 UV 
spectrophotometer 
pH tester 1 (water proof) Oakton instruments. 
 
Method 
The required amount of drug and the other additives were 
mixed thoroughly in a mortar and the tablets are prepared by 
direct compression using Rimek Mini Press 1 punching 
machine. The prepared tablets were stored in screw capped 
glass bottles. The prepared tablets were evaluated for 
dissolution characteristics. 
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EVALUATION OF TABLETS 
The formulated tablets were subjected for the following 
quality control tests.37,57  
•  Weight variation  
•  Disintegration test 
•  Friability 
•  Hardness 
•  Drug content uniformity 
•  Dissolution  
Weight variation test 
Twenty tablets were taken weighed individually. They 
were evaluated for the weight variations. The weight variation 
allowed as IP limit is  ± 5%. The weight of tablets with in the IP 
limits. The results were shown in table 32. 
Disintegration test  
The USP device to test disintegration uses six glass tubes 
that are three inches long open at the top and held against 10 
inch screen at the basket rack assembly. A tablet is placed in 
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each tube and the basket is positioned in a 1 litre beaker of 
distilled water at 37±2°C, such that the tablets below the surface 
of the liquid on their movement and descend not closer than  
2.5 cm from the bottom of the tester. The disintegration time is  
4 min. 45 sec. The results were shown in table .32 
Friability test 
Friability test was performed on the formulated tablets. 
The weight of the tablets after undergoing 100 revolutions was 
found to be within the limits 0.5 to 1.0%. The results were 
shown in table. 32 
Hardness  
Pfizer hardness tester was used for measuring the 
hardness of formulated Etodolac solid dispersion tablets. Five 
tablets were taken randomly and subjected to test. The 
hardness was found to be 4-5 kg/cm2. The results were shown 
in table. 32. 
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Drug content uniformity 
The prepared tablets containing Etodolac  solid dispersion 
was tested for drug content uniformity. Tablets were dissolved 
in 100 ml of pH 6.8 phosphate buffer in 100 ml volumetric flask 
which was previously clean and dry. This solution after suitable 
dilution was measured for absorbance at 274 nm in a Jasco 
V530 UV visible spectrophotometer. The results were shown in 
table. 32 
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Table : 32 Weight variation, disintegration  time, friability, hardness and drug content uniformity 
of tablets containing solid dispersions of Etodolac 
S. No. 
Weight 
variation(%),weight 
range  of tablets (mg) 
Disintegration 
time  (sec) 
Friability (%of 
loss of weight) 
Hardness 
(kg/cm2) 
Drug content 
uniformity (%) 
1 710 285 0.51 4.3 98.1 
2 713 270 0.60 4.2 94.5 
3 722 300 0.63 4.1 92.4 
4 678 303 0.52 4.8 93.6 
5 685 280 0.54 4.9 90.6 
6 691 288 0.57 4.5 94.5 
7 718 290 0.65 4.6 95.4 
8 704 294 0.7 4.7 99.3 
9 697 298 0.50 4.3 93.0 
10 690 301 0.65 4.4 97.2 
11 680 305 0.67 4.0 99.0 
12 727 309 0.55 4.6 92.4 
13 709 299 0.53 4.1 100.2 
14 715 291 0.59 4.5 94.5 
15 695 289 0.64 4.9 92.4 
16 674 296 0.68 4.3 93.6 
17 707 295 0.69 4.2 94.5 
18 689 306 0.8 4.0 99.0 
19 702 310 0.72 4.4 97.4 
20 698 293 0.66 4.8 92.5 
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In-vitro Dissolution studies 
Dissolution of Etodolac  from various tablets was studied in USP 
dissolution medium. The tablets containing solid dispersions equivalent to 
100mg of Etodolac were taken and the paddle type stirrer was adjusted to 
100 rpm. The temperature was maintained at 37±0.5°C. 10 ml aliquot 
dissolution media was withdrawn at different time intervals and volume 
withdrawn was replaced with fresh quantity of dissolution media. The 
samples were analyzed for Etodolac by measuring absorbance at 274 nm 
using Jasco UV visible spectrometer. pH 6.8 phosphate buffer was used 
as blank.39 The percentage of Etodolac  dissolved at various time intervals 
was calculated and plotted against time. The results are shown in table 33 
and fig.44 
Table : 33  Dissolution profile of Etodolac from tablet formulation and 
from marketed tablets 
Percentage of Etodolac released from Time in 
minutes Tablet formulation Marketed tablet 
0 0 0 
5 32.5 21.6 
10 53.6 46.3 
15 68.5 54.9 
30 91.7 67.5 
45 97.8 84.7 
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Fig: 44  Dissolution profile of Etodolac from tablet formulation and 
from marketed tablets 
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RESULTS AND DISCUSSION 
 The tablets were formulated using solid dispersion at 1:19 ratio with PGS 
( Potato ) by kneading method. 
 All the batches fulfill the official IP requirements for tablets. 
Hardness of the tablets in all the batches was found to be 4 to 5 kg/cm2 
and was satisfactory. The percentage weight loss in the friability test was 
found to be less than 1 % in all batches. Thus the tablets prepared were 
found to be good quality and fulfilling all the official requirements of 
compressed tablets. 
The dissolution profile of various tablets formulated employing, 
Etodolac: PGS (Potato) dispersions at 1:19 ratio by kneading method and 
marketed tablet were shown in table 33. Tablets formulated with solid 
dispersions gave rapid dissolution of the medicament when compared to 
the marketed tablets The dissolution rate was found to be high in the case 
of tablets formulated employing solid dispersions indicating rapid and 
higher dissolution of the medicament from these tablets when compared to 
the marketed tablets. 
Summary & Conclusion 
 114
SUMMARY AND CONCLUSION 
Studies were under taken on the preparation and evaluation of solid 
dispersions of Etodolac with view to develop fast release formulation of 
Etodolac. Three carriers viz PGS( Potato), PGS (Tapioca) and PGS 
(Maize) were used to prepare the solid dispersions of Etodolac by solvent 
evaporation and kneading method at various drug: carrier ratios namely 
(1:1,1:3,1:9 and 1:19). The solid dispersions prepared were found to be 
fine and free flowing powders. X-ray diffraction studies revealed that 
crystalline nature of Etodolac in pure form was reduced to amorphous form 
in the dispersions The thermal behavior of Etodolac: PGS (Potato) solid 
dispersion was studied using DSC indicating that Etodolac has complexed 
with PGS (Potato). This phenomenon is indicative of stronger interaction 
between Etodolac and PGS (Potato) in the solid state. Interaction studies 
like TLC, FTIR indicated no interaction between drug and polymer used.  
Results of dissolution studies showed rapid and fast dissolution of 
Etodolac from all solid dispersions when compare with pure drug and 
physical mixture. Good correlation was absorbed between percentage 
carrier in the solid dispersion and T50 and T90 values. Among the three 
carriers PGS (Potato) gave highest dissolution rate in the drug carrier ratio 
of 1:19.  
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The order of dissolution of Etodolac from various carriers is PGS 
(Potato) KM > PGS (Potato) SE> PGS (Tapioca) SE> PGS (Tapioca) KM> 
PGS( Maize) KM> PGS( Maize )SE. 
 Etodolac solid dispersion in PGS (Potato) (1:19) was formulated 
into tablets with usual additives and the tablets were evaluated for 
dissolution characteristics .The dissolution of Etodolac from tablet 
formulation based on solid dispersion was found to be fast and rapid when 
compared to marketed tablet. 
The additives added have not hindered the dissolution of Etodolac 
from solid dispersions. All the tablet formulations based on the solid 
dispersion fulfilled the official dissolution requirements. Hence the tablet 
formulations based on solid dispersions are considered as fast release 
dosage of Etodolac.  
In this work it was concluded that the Etodolac tablets formulated 
employing Etodolac: PGS (Potato ) solid dispersion gave comparable 
dissolution when compared to the marketed samples.Moreover, the carrier 
used in the present study is pre-gelatinized starch.It is a low cost carrier so 
that we can reduce the cost of production significantly.  
 
 
References 
REFERENCES 
1. Toshio ohara, Satoshi kitamura, Teruyuki Kitagawa, Katsuhide 
Terada.Dissolution mechanism of poorly water-soluble drug from 
extended release solid dispersion system with ethylcellulose and 
hydroxyl propyl methyl cellulose.IJP 2005 ; 302: 95-6. 
2. Christian Leuner, Jennifer Dressman. Improving drug solubility 
 for oral delivery using solid dispersions. EJPB 2000; 50: 47-8. 
3. Dimitrios Bikiaris, George z. papageorgiou, Anagnostis stergiou, 
Eleni pavlidou, Evangelos karavas, Ferras kanaze etal. 
Physicochemical studies on solid dispersions of poorly water-
soluble drugs Evaluation of capabilities and limitations of thermal 
analysis techniques.thermochimica acta 2005; 439: 58-9 
4. Chowdary  KPR, Rama Rao N. Formulation and Evaluation of 
Nifedipine tablets employing nifedipine-pregelatinized starch 
dispersions. Indian drugs, 1999; 37 (8): 371-72 
5. Muhammad. J.Habib.Historical background of solid dispersion in 
pharmaceutical solid dispersion technology Pennsylvania: Inc. 
Lancaster. Technomic publishing company; 2001.p.1 
6. Noyes A.A., Whitney W.R., 1897 “The rate of solution of solid 
 substances in their own solutions”, J. Am. Chem. Soc. 19:930-934. 
7. Nernst W, 1904., “Theorie der Reaktionsgeschwindigkeit in 
heterogenen Systemen”, eitschrift f. Physik. Chemie 47:52-55. 
References 
8. Galia.E., Nicolaides.E, HoÈrter.D, LoÈbenberg. R., Reppas C., 
Dressman J.B, 1998. “Evaluation of various dissolution media for 
predicting in vivo performance of class I and II drugs”, Pharm. 
Res.15:698- 705. 
9. Sekiguchi. K,Obi .N, 1961. “Studies on absorption of eutectic 
mixtures . I.A comparison of the behavior of eutectic mixtures of 
sulphathiazole and that of ordinary sulphathiazole in man”,Chem. 
Pharm. Bull. 9:866-872. 
10. Goldberg.A.H., Gibaldi.M, Kanig.J.L, 1966. “Increasing dissolution 
rates and gastrointestinal absorption of drugs via solid solutions and 
eutectic mixtures II - experimental evaluation of a eutectic mixture: 
urea-acetaminophen system” , J. Pharm. Sci. 55:482-487. 
11. Goldberg.A.H., Gibaldi.M., Kanig.J.L, 1965. “Increasing dissolution 
rates and gastrointestinal absorption of drugs via solid solutions and 
eutectic mixtures I -theoretical considerations and discussion of the 
literature”, J. Pharm. Sci. 54:1145-1148. 
1.2 Hume-Rotherly W, Raynor.G.V, 1954. “The Structure of Metals and 
 Alloys”, Institute of Metals, London,  
13. Reed-Hill R.E., 1964. “Physical Metallurgy Principles”, Van-Nostrad, 
 Princetown, NJ, 
14. Chiou W.L., Riegelman.S, 1969, “Preparation and dissolution 
characteristics of several fast-release solid dispersions of 
griseofulvin”, J. Pharm. Sci. 58:1505-1510. 
References 
15. Sekiguchi. K., Obi N., 1961. “Studies on absorption of eutectic 
mixtures, I.A comparison of the behavior of eutectic mixtures of 
sulphathiazole and that of ordinary sulphathiazole in man”, Chem. 
Pharm. Bull. 9:866-872. 
16. Chiou, W. I, and Riegelman, S.1970.”Oral absorption of griseofulvin 
in dogs: increased absorption via solid dispersion in poly ethylene 
glycol 6000.” J. Pharm. Sci., 59(7)):937-42.  
17. Malone, M.H,Hochman, H.I. and Nieforth, K.A. 1966.”Desoxycholic 
acid enhancement of orally administered reserpine. ” J.Pharm.Sci. 
55(9):972-4. 
18. Graf, E., Beyer, C. and Abdallah, O. 1982. “Solid dispersions of 
acetohexamide. 3. Acetohexamide –poly (vinyl pyrrolidone). 
Methods of preparation and solvent used.” Acta Pharm. Tech., 
28:225-30. 
19. Bloch, D. W., Elegakey, M.A. and Speiser, P. 1983.”Spray dried 
solid dispersions of hydrochlorthiazide and chlorthalidone in 
pentaerythritol.” Pharm. Acta Helv., 58:14-22. 
20. Takayama, K. , Nambu, N. and Nakai, T. 1982.”Factors affecting 
the dissolution of ketoprofen from solid dispersions in various water 
soluble polymers.” Chem. Pharm. Bull., 30:3013-6.  
21. Sekikawa.H., Fukuda. W., Takada.M, Ohtani.K., Arita, and Nakano, 
N.1983.”Dissolution behavior and gastrointestinal absorption of 
dicumarol from solid dispersion systems of dicumarol-poly vinyl 
References 
pyrrolidone and dicumarol-beta cyclodextrin.” Chem. Pharm. Bull. 
(Tokya), 31(4):1350-6. 
22. Chiou, W.I. and Riegelman, S. 1971. “Pharmaceutical applications 
of solid dispersion systems” J. Pharm. Sci., 60(9):1281-302. 
23. Brahmankar DM, Sunil B. Jaiswal. Biopharmaceutics and 
pharmacokinetics A Treatise. New Delhi: M K Jain for Vallabh 
prakashan ; 1995 . p. 8-14. 
24. Larry LA, Stephen WH. Pharmaceutical Dosage forms: Tablets 3 rd 
ed. New York: Informa Health care USA, Inc; 2008. P.231-4 
(Rational Design and Formulation; Vol 2). 
25. Goodman and Gilman,s , 2001 , Analgesics, antipyretic and anti- 
inflammatory agents and drugs employed in the treatment of gout , 
in : 10th edition , Harman Joel G and Limbird Lee E . (Eds.), the 
pharmacological Basis of Therapeutics, MC Graw Hill Companies, 
INC; p. 687 – 95. 
26. Tripathi K.D., 2004, Non steroidal anti inflammatory drugs and 
antipyretic –analgesics, in: 5th edition, K.D. Tripathi (edr.), 
Essentials of Medical Pharmacology, Jaypee Brothers Medical 
Publishers (P) Ltd., pp. 167-170.  
27. Brocks DR, Jamali F. Clin. Pharmacokinet. 26 (4)  1994. p. 263 - 71 
28. http: // www.RX list .com 
29. Raymond CR, Paul JS, Pal JW, Handbook of  Pharmaceutical 
 excipients. 4 th ed. London: Science and Practice; 2003 .p. 609-11 
References 
30. http : // creative commons . org / licenses / by / 2.0 
31. The United States pharmacopoeia (2004), Asian edition. p.770 – 2 
32. European pharmacopoeia (2004), Council of Europe, 5th 
 ed.Vol.2. . p. 1560 – 1 . 
33. British Pharmacopoeia (2003), Vol 3, published by HMSO: 
 London; UK. p. 2308 – 10. 
34. O , Neil MJ , Smith A , Heckel PE , Obenchain JR , Gallipeau JR , 
D.  Arecca MA, editors. The Merck Index. Merck Research 
Laboratories, Division of Merck & Co; INC; 2001. 13th ed.  
P. 684 . 
35. Martindale, The complete drug reference, 32nd Edition, 
 Pharmaceutical press , London. 
36. Sharma YR . Elementary organic spectroscopy. 4 th ed . New 
 Delhi : S . chand and company Ltd ; 2007 . P . 89 – 90. 
37. Indian Pharmacopoeia 1996 , Ministery of Health & Family 
 welfare. The controller of publications , Delhi . Vol 2 A - 144 – 5. 
38. Vijaya kumar SG, Mishra DN . preparation and Evaluation of  soli.d 
 dispersion of meloxicam with skimmed milk. IJPS .2005 ;126 :  
 93- 7. 
39. Okonogi S , Puttipipatkhachorn S . Dissolution improvement of high 
drug- loaded solid dispersion . AAPS pharm Sci Tech . 2006  
Mar 29 ; 7 9( 2) : 44 – 54  
References 
40. Patel MM, Patel DM. Fast dissolving Valdecoxib tablets 
 containing solid dispersion of valdecoxib. IJPS . 2006 ; 68 ( 2 ) : 
 222 – 6. 
41. Wang, Zhao, Fusheng. Solid dispersion of Glibenclamide, its 
 oral composition and methods Eur . J . pharm . Sci . 28 : 67 – 76.  
42. Barakat NS. Etodolac-liquid-filled dispersion into hard gelatin 
 capsules : an approach to improve dissolution and stability of 
 etodolac formulation.Drug Dev Ind pharm. 2006 ; 32 ( 7 ) : 865-76. 
43. Uchino T, Yasuno N, Yanagihara Y, Suzuki H. solid dispersion 
 of spironolactone with porous silica prepared by the solvent 
 method. Pharmazie . 2007 Aug ; 62 ( 8 ) : 599- 603. 
44. Zijlstra GS, Rijkeboer M, Van Drooge DJ , Sutter M, Jiskoot W et al.  
Characterization of a cyclosporine solid dispersion for inhalation . 
AAPS . 2007 ; 9 ( 2 ) : 190 – 3. 
45. Lee M , Chang H , Kim T , Park J , Lee B et al . Biopharmaceutical 
evaluation of a solid dispersion system containing sibutramine 
freebase . Bull. Korean .chem . soc . 2007 ; 29 ( 4 ) : 749 – 51. 
46. Shah TJ, Amin AF, Parikh JR, Parikh RH . process optimization and 
characterization of poloxamer solid dispersions of a poorly water- 
soluble drug. AAPS pharm Sci Tech . 2007 ; 8 ( 2 ) : 42 – 5 . 
47. Rane Y, Mashru R, Sankalia M, Sankalia J. Effect of hydrophilic 
swellable polymers on dissolution enhancement of carbamazepine 
References 
solid dispersions studied using response surface technology. AAPS 
pharm Sci Tech . 2007 ; 8 ( 2 ) : 651-71. 
48. Vittadini E, Carini E, Chiavaro E, Rovere p, Barbanti D. High 
pressure induced tapioca starch gels : physico- chemical 
characterization and stability . Eur . J. pharm . Sci . 2007 ; 226 : 339 
– 56. 
49. Tran T, Thitipraphunkul K, Piyachomkwank. Effect of starch 
modifications and hydro colloids on freezable water in cassava 
starch systems. IJPS . 2007 ; 9 ( 1 ) : 140 – 5. 
50. Nakhat PD, Naidu RA, Khan S, Yeole PG. Design and evaluation of 
Silymarin-HP-β-CD Solid dispersion tablets. Ind. J.pharm. 2007 ; 69 
( 2 ) ; 287 – 9. 
51. Murli SV, Chavan PV, Joshi JB. solid dispersion studies in 
expanded beds. Ind . Eng . chem. . Res . 2007 ; 46 ( 6 ) : 1836 – 
42. 
52. Moneghini M, Bellich B, Baxa P, Princivalle F.Micro wave generated 
solid dispersions containing ibuprofen. IJP . 2008 sep ; 361 ( 2 ): 
125 – 30. 
53. Oluwatovin A, Odeku, Schmid W et al. Material and tablet 
properties of pregelatinized (thermally modified) Dioscorea 
starches, cham . pharm . Bull , 2008 ; 30 : 316 – 9. 
References 
54. Aubin HT , Zhu X. NMR spectroscopy and imaging studies of 
pharmaceutical tablets made of starch. IJPS. 2008;7  
( 1 ) : 14 – 22. 
55. Xie Y , Tang X , Song H . Preparation of esomeprazole Zinc solid 
dispersion and study on its pharmacokinetics . Eur . J .pharm .Sci. 
2008 ; 179 :96 – 98. 
56. Biswal S , Sahoo J , Murthy PN , Giradkar RP , Avari JG . 
Enhancement of dissolution rate of gliclazide using solid 
dispersions with PEG 6000 . IJPS ; 2008 ; 32 ( 1 ) : 42 - 50. 
57. Leon Lachman , Herbert A Liberman , Joseph L . kanig , The theory 
and practice of Industrial pharmacy , 3 rd ed. P. 293 – 303 . 
Abbreviations 
ABBREVIATIONS 
 
ETD    - Etodolac 
PGS    - Pre-gelatinized starch 
SD    - Solid Dispersion 
PM   - Physical Mixture 
IR   - Infra Red 
DSC   - Differential Scanning Calorimetry 
SEM                         -          Scanning Electron Microscopy 
SE   - Solvent Evaporation Method 
KM   - Kneading Method 
TLC   - Thin Layer Chromatography 
 
 
